Subscribe

Labcorp Holdings Inc. (LH)

USD276.68 -0.13 (-0.05%)
US NYSE S&P 500 Healthcare Medical - Diagnostics & Research
Address 358 South Main Street 27215
Burlington, NC, US
CEO Adam H. Schechter
Website labcorp.com
IPO 1990-03-29
CIK 920148 ISIN US5049221055

Explore sections of this company profile

Also trades on London Stock Exchange · 0JSY.L (USD) New York Stock Exchange · LH (USD)
Description

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.

News Sentiment (7d)
75 Positive

3 articles

Market Cap & Enterprise Value
Merger & Acquisition History
Target company Ticker Date Filing
Rule — 1994-03-14 View
NantHealth, Inc. NH 1995-03-30 View
Cravath CVD 2014-11-26 View

Index membership

IndexAddedRemovedStatus
S&P 500 2004-10-29 — Active
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD276.68 -0.13 (-0.05%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
655.4K
Beta
0.86
Float Shares
81.90M
Free Float %
99.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.89% +0.59% -1.37% -7.46% -3.25% +2.58% +2.55% +35.69% +10.17% +138.20% +1,128.99%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (35 ratings, all time) Buy
Price Targets & DCF
Current price
276.68
Low 300.00 +8.4%
Consensus 311.33 +12.5%
Median 300.00 +8.4%
High 334.00 +20.7%
DCF (Unlevered) 414.44 +49.8%
DCF (Levered) 443.81 +60.4%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 74% Bullish
Rating 2026-05 Change
Strong Buy 2 0
Buy 12 0
Hold 5 0
Sell 0 0
Strong Sell 0 0
Price Target Summary
Period # Analysts Avg Target
Last Month 1
334.00
+20.7%
Last Quarter 4
315.00
+13.8%
Last Year 16
311.88
+12.7%
All Time 33
300.21
+8.5%
Quality scores
Altman Z-Score
2.95
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Diagnostics & Research: +7.9%
    +7.3% Q1'26: +5.8% (vs Q1'25)
  • ✓
    EPS growth Medical - Diagnostics & Research: +30.8%
    +18.3% Q1'26: +32.9% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    +4.3% Q1'26: +2.0% (vs Q1'25)
  • ✗
    EBIT margin Medical - Diagnostics & Research: +9.6%
    +9.5% Q1'26: +10.9% (vs Q1'25)
  • ✗
    ROIC Medical - Diagnostics & Research: +5.2%
    +6.9% ★ Q1'26: +9.0% (vs Q1'25)
  • ✓
    Share dilution Medical - Diagnostics & Research: 0.0%
    -0.7% ★ Q1'26: -1.7% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    3.58× Q1'26: 3.23× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.88) × ERP
WACC = 75% × Ke + 25% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 407.31 Current price: 276.68
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
14 Rev. Ana.
12 EPS Ana. 		Dec 2027
14 Rev. Ana.
12 EPS Ana. 		Dec 2028
12 Rev. Ana.
8 EPS Ana. 		Dec 2029
11 Rev. Ana.
6 EPS Ana. 		Dec 2030
6 Rev. Ana.
6 EPS Ana.
Revenue
5.54B
est: 5.44B (+1.8%)
5.67B
est: 5.59B (+1.5%)
5.81B
est: 5.87B (-1.0%)
6.01B
est: 6.01B (+0.1%)
8.68B
est: 8.49B (+2.3%)
9.64B
est: 9.40B (+2.5%)
10.44B
est: 10.19B (+2.5%)
11.33B
est: 11.33B (+0.1%)
11.55B
est: 11.53B (+0.2%)
13.98B
est: 13.54B (+3.2%)
13.14B
est: 16.01B (-17.9%)
11.86B
est: 14.94B (-20.6%)
12.16B
est: 12.49B (-2.6%)
13.01B
est: 12.99B (+0.2%)
13.95B
est: 13.99B (-0.3%)
14.69B
14.64B – 14.79B
+5.0% YoY
15.40B
15.14B – 15.64B
+4.8% YoY
16.11B
16.09B – 16.13B
+4.6% YoY
17.13B
16.96B – 17.32B
+6.3% YoY
15.22B
15.07B – 15.39B
-11.1% YoY
EBITDA
1.18B
est: 1.15B (+2.7%)
1.26B
est: 1.25B (+1.0%)
1.24B
est: 1.25B (-1.1%)
1.18B
est: 1.18B (-0.2%)
1.58B
est: 1.43B (+9.9%)
1.81B
est: 1.81B (-0.3%)
1.85B
est: 1.85B (-0.3%)
2.06B
est: 2.06B (+0.3%)
2.12B
est: 1.88B (+12.4%)
3.25B
est: 1.81B (+79.5%)
3.68B
est: 3.25B (+13.0%)
1.95B
est: 3.00B (-34.8%)
1.35B
est: 2.10B (-35.6%)
1.81B
est: 2.18B (-16.9%)
2.01B
est: 2.35B (-14.3%)
2.47B
2.46B – 2.48B
+5.0% YoY
2.58B
2.54B – 2.62B
+4.8% YoY
2.70B
2.70B – 2.71B
+4.6% YoY
2.88B
2.85B – 2.91B
+6.3% YoY
2.55B
2.53B – 2.58B
-11.1% YoY
EBIT
953.60M
est: 930.98M (+2.4%)
1.04B
est: 1.01B (+3.1%)
1.01B
est: 1.00B (+1.2%)
930.10M
est: 908.43M (+2.4%)
1.00B
est: 984.05M (+1.7%)
1.32B
est: 1.31B (+0.8%)
1.31B
est: 1.33B (-1.4%)
1.51B
est: 1.31B (+15.0%)
1.35B
est: 1.30B (+3.1%)
2.43B
est: 1.42B (+71.2%)
3.10B
est: 2.60B (+19.2%)
1.42B
est: 2.37B (-40.3%)
768.50M
est: 1.51B (-49.1%)
1.17B
est: 1.57B (-25.6%)
1.33B
est: 1.69B (-21.2%)
1.78B
1.77B – 1.79B
+5.0% YoY
1.86B
1.83B – 1.89B
+4.8% YoY
1.95B
1.94B – 1.95B
+4.6% YoY
2.07B
2.05B – 2.09B
+6.3% YoY
1.84B
1.82B – 1.86B
-11.1% YoY
Net Income
519.70M
est: 510.23M (+1.9%)
583.10M
est: 573.88M (+1.6%)
573.80M
est: 579.18M (-0.9%)
511.20M
est: 510.02M (+0.2%)
436.90M
est: 431.01M (+1.4%)
732.10M
est: 717.94M (+2.0%)
1.27B
est: 1.23B (+2.7%)
883.70M
est: 883.43M (+0.0%)
823.80M
est: 807.81M (+2.0%)
1.56B
est: 873.20M (+78.2%)
2.38B
est: 1.89B (+26.0%)
1.28B
est: 1.74B (-26.3%)
418.00M
est: 449.50M (-7.0%)
746.00M
est: 1.22B (-38.6%)
876.50M
est: 1.37B (-35.9%)
1.51B
1.49B – 1.54B
+10.6% YoY
1.61B
1.56B – 1.67B
+6.8% YoY
1.80B
1.59B – 2.01B
+11.5% YoY
1.98B
1.95B – 2.00B
+9.7% YoY
2.05B
2.02B – 2.08B
+3.8% YoY
SGA
1.16B
est: 1.14B (+1.8%)
1.11B
est: 1.10B (+1.5%)
1.13B
est: 1.14B (-1.0%)
1.20B
est: 1.20B (+0.1%)
1.62B
est: 1.56B (+4.1%)
1.63B
est: 1.62B (+0.9%)
1.81B
est: 1.77B (+2.5%)
1.57B
est: 1.56B (+1.0%)
1.62B
est: 1.59B (+2.0%)
1.73B
est: 1.11B (+55.5%)
1.69B
est: 1.55B (+8.9%)
2.00B
est: 1.78B (+12.5%)
2.02B
est: 1.98B (+2.0%)
2.23B
est: 2.06B (+8.2%)
2.22B
est: 2.22B (-0.2%)
2.33B
2.32B – 2.35B
+5.0% YoY
2.44B
2.40B – 2.48B
+4.8% YoY
2.56B
2.55B – 2.56B
+4.6% YoY
2.72B
2.69B – 2.75B
+6.3% YoY
2.42B
2.39B – 2.44B
-11.1% YoY
EPS
5.31
est: 6.11 (-13.1%)
6.24
est: 6.70 (-6.9%)
6.70
est: 7.09 (-5.5%)
6.03
est: 6.72 (-10.3%)
4.42
est: 6.78 (-34.8%)
7.14
est: 7.55 (-5.4%)
12.39
est: 8.19 (+51.3%)
8.71
est: 9.45 (-7.8%)
8.41
est: 9.67 (-13.0%)
15.99
est: 18.41 (-13.1%)
24.58
est: 23.84 (+3.1%)
14.04
est: 17.07 (-17.8%)
4.80
est: 5.30 (-9.4%)
8.89
est: 14.52 (-38.8%)
10.54
est: 16.33 (-35.5%)
18.01
17.72 – 18.35
+10.3% YoY
19.49
18.58 – 19.96
+8.2% YoY
21.19
19.03 – 23.96
+8.7% YoY
23.58
23.27 – 23.90
+11.3% YoY
24.46
24.14 – 24.80
+3.8% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 B+ 3/5 4/5 4/5 4/5 1/5 2/5 3/5
2026-05-08 B+ 3/5 4/5 4/5 4/5 1/5 2/5 3/5
2026-05-07 B+ 3/5 4/5 4/5 4/5 1/5 2/5 3/5
2026-05-06 B+ 3/5 4/5 4/5 4/5 1/5 2/5 3/5
2026-05-05 B+ 3/5 4/5 4/5 4/5 1/5 3/5 3/5
2026-05-04 B+ 3/5 4/5 4/5 4/5 1/5 3/5 3/5
2026-05-01 B+ 3/5 4/5 4/5 4/5 1/5 3/5 3/5
2026-04-30 B+ 3/5 4/5 4/5 4/5 1/5 3/5 3/5
2026-04-29 B+ 3/5 4/5 3/5 4/5 1/5 3/5 3/5
2026-04-28 B+ 3/5 4/5 3/5 4/5 1/5 3/5 3/5
2026-04-27 B+ 3/5 4/5 3/5 4/5 1/5 3/5 3/5
2026-04-24 B+ 3/5 4/5 3/5 5/5 1/5 3/5 3/5
2026-04-23 B+ 3/5 4/5 3/5 5/5 1/5 2/5 3/5
2026-04-22 B+ 3/5 4/5 3/5 5/5 1/5 2/5 3/5
2026-04-21 B+ 3/5 4/5 3/5 5/5 1/5 2/5 3/5
2026-04-20 B+ 3/5 4/5 3/5 5/5 1/5 2/5 3/5
2026-04-17 B+ 3/5 4/5 3/5 5/5 1/5 2/5 3/5
2026-04-16 B+ 3/5 4/5 3/5 5/5 1/5 2/5 3/5
2026-04-15 B+ 3/5 4/5 3/5 5/5 1/5 2/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.60B
OE per share TTM
19.13
Owner's Yield
7.62%
Maintenance CapEx ratio
28.11%
Maint CapEx / Avg PPE
22.3%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
386
Total invested
1.35B
Insider transactions (90d)
0
Beneficial owners (>5%)
17
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 The Vanguard Group - 23-1945930 10.75M 11.24% — 152.7K 10.37M 387.4K IA Pennsylvania For 2022-02-10 ↗
2 (1) BlackRock, Inc. 9.71M 10.40% 8.76M — 9.71M — HC Delaware 2022-03-09 ↗
3 85-0360310 9.56M 10.90% 9.07M — 9.56M — IA Colorado 2014-01-09 ↗
4 13-3043476 7.43M 3.36% — — — — IA, CO DELAWARE 2004-10-12 ↗
5 WILLIAM C. MORRIS 7.43M 3.36% — — — — IN UNITED STATES 2004-10-12 ↗
6 Harris Associates Inc. 04-3276549 7.41M 7.28% 7.41M — 7.41M — CO Delaware 2011-02-08 ↗
7 Harris Associates L.P. 04-3276558 7.41M 7.28% 7.41M — 7.41M — IA Delaware 2011-02-08 ↗
8 52-0556948 5.94M 5.80% 1.82M — 5.94M — IA MARYLAND 2011-02-10 ↗
9 Viking Global Investors LP 5.40M 5.30% — 5.40M — 5.40M PN Delaware 2015-10-13 ↗
10 LAWRENCE M. ROBBINS 5.35M 5.29% — 5.35M — 5.35M HC, IN Delaware 2015-11-19 ↗
11 Laboratory Corporation of America Holdings 4.86M 9.80% — 4.86M — 4.86M CO — 2023-03-27 ↗
12 GLENVIEW CAPITAL MANAGEMENT, LLC 4.19M 4.07% — 4.19M — 4.19M OO Delaware 2017-02-14 ↗
13 LARRY ROBBINS 4.19M 4.07% — 4.19M — 4.19M HC, IN Delaware 2017-02-14 ↗
14 Boston Partners 3.30M 3.27% 2.40M 1.4K 3.30M — IA Delaware 2019-02-12 ↗
15 Chieftain Capital Management, Inc. 13-3194313 3.03M 2.90% — 3.03M — 3.03M IA, CO New York, United States 2010-04-08 ↗
16 EIN #75-3019302 1.55M 1.30% — 1.55M — 1.55M IA, HC Delaware 2008-02-14 ↗
17 04-3276549 123.9K 0.10% 117.4K — 117.4K — CO Delaware 2015-02-11 ↗

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
386
-632 vs prev Q
New positions
30
Closed positions
652
Increased
145
Reduced
126
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 VANGUARD GROUP INC 9.85M +37.2K (+0.4%) 2.47B -345.7M (-12.3%) 11.84% +0.087 pp 0.04% -0.006 pp USD204.55 +22.6% 7 qtrs —
2 BLACKROCK, INC. 6.54M -1.6M (-19.5%) 1.64B -691.6M (-29.6%) 7.86% -1.870 pp 0.03% -0.013 pp USD223.59 +12.2% 6 qtrs —
3 VICTORY CAPITAL MANAGEMENT INC 5.36M +2.7M (+103.1%) 1.34B +587.0M (+77.6%) 6.45% +3.288 pp 0.76% +0.316 pp USD258.00 -2.8% 7 qtrs —
4 STATE STREET CORP 3.83M -5.6K (-0.1%) 959.95M -140.0M (-12.7%) 4.60% +0.010 pp 0.03% -0.006 pp USD204.76 +22.5% 7 qtrs —
5 ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC 2.20M +208.0K (+10.4%) 554.73M -2.4M (-0.4%) 2.65% +0.259 pp 0.90% +0.004 pp USD212.38 +18.1% 7 qtrs —
6 GEODE CAPITAL MANAGEMENT, LLC 2.14M +13.8K (+0.6%) 534.02M -72.9M (-12.0%) 2.57% +0.026 pp 0.03% -0.006 pp USD206.57 +21.5% 7 qtrs —
7 SELECT EQUITY GROUP, L.P. 2.11M +273.7K (+14.9%) 529.55M +2.2M (+0.4%) 2.54% +0.337 pp 2.28% +0.110 pp USD228.60 +9.7% 7 qtrs —
8 WELLINGTON MANAGEMENT GROUP LLP 1.96M -142.7K (-6.8%) 492.50M -112.0M (-18.5%) 2.36% -0.160 pp 0.09% -0.020 pp USD258.42 -2.9% 7 qtrs —
9 BOSTON PARTNERS 1.91M +1.9M (+100.0%) 480.27M +480.3M (+100.0%) 2.30% +2.303 pp 0.50% +0.497 pp USD250.88 +0.0% 1 qtrs NEW
10 MORGAN STANLEY 1.51M -1.8K (-0.1%) 377.71M -55.0M (-12.7%) 1.81% +0.004 pp 0.02% -0.004 pp USD207.65 +20.8% 7 qtrs —
11 INVESCO LTD. 1.39M +91.9K (+7.1%) 349.22M -24.0M (-6.4%) 1.67% +0.116 pp 0.05% -0.005 pp USD212.54 +18.0% 7 qtrs —
12 FMR LLC 1.34M -108.5K (-7.5%) 336.12M -79.6M (-19.2%) 1.61% -0.122 pp 0.02% -0.005 pp USD208.29 +20.4% 7 qtrs —
13 DIMENSIONAL FUND ADVISORS LP 1.30M +57.6K (+4.6%) 327.21M -30.6M (-8.5%) 1.57% +0.077 pp 0.07% -0.008 pp USD205.89 +21.9% 7 qtrs —
14 JPMORGAN CHASE & CO 1.29M +213.1K (+19.8%) 322.93M +14.6M (+4.7%) 1.55% +0.263 pp 0.02% +0.002 pp USD214.12 +17.2% 7 qtrs —
15 DIAMOND HILL CAPITAL MANAGEMENT INC 1.26M -382.1K (-23.3%) 316.14M -155.3M (-32.9%) 1.52% -0.450 pp 1.62% -0.618 pp USD203.43 +23.3% 7 qtrs —
16 ALLIANCEBERNSTEIN L.P. 1.06M -39.1K (-3.5%) 266.61M -49.7M (-15.7%) 1.28% -0.042 pp 0.08% -0.015 pp USD219.56 +14.3% 7 qtrs —
17 VERITAS INVESTMENT PARTNERS (UK) LTD. 1.03M -30.4K (-2.9%) 257.69M -45.9M (-15.1%) 1.24% -0.031 pp 5.44% -0.372 pp USD204.42 +22.7% 7 qtrs —
18 NORTHERN TRUST CORP 1.01M -17.3K (-1.7%) 254.55M -41.7M (-14.1%) 1.22% -0.015 pp 0.03% -0.005 pp USD206.89 +21.3% 7 qtrs —
19 NORGES BANK 988.5K +988.5K (+100.0%) 248.01M +248.0M (+100.0%) 1.19% +1.190 pp 0.03% +0.027 pp USD250.88 +0.0% 1 qtrs NEW
20 NORDEA INVESTMENT MANAGEMENT AB 967.7K -553.3K (-36.4%) 243.04M -189.3M (-43.8%) 1.16% -0.657 pp 0.21% -0.170 pp USD223.22 +12.4% 7 qtrs —
21 UBS ASSET MANAGEMENT AMERICAS INC 872.5K -10.2K (-1.2%) 218.89M -34.5M (-13.6%) 1.05% -0.007 pp 0.05% -0.009 pp USD208.09 +20.6% 7 qtrs —
22 AMERICAN CENTURY COMPANIES INC 819.5K +53.1K (+6.9%) 205.60M -14.4M (-6.6%) 0.99% +0.068 pp 0.10% -0.009 pp USD210.72 +19.1% 7 qtrs —
23 COOKE & BIELER LP 752.9K -1.5K (-0.2%) 188.89M -27.7M (-12.8%) 0.91% +0.003 pp 1.97% -0.267 pp USD203.43 +23.3% 7 qtrs —
24 BANK OF AMERICA CORP /DE/ 736.3K +10.2K (+1.4%) 184.73M -23.7M (-11.4%) 0.89% +0.015 pp 0.01% -0.001 pp USD214.27 +17.1% 7 qtrs —
25 ROYAL BANK OF CANADA 686.9K -121.1K (-15.0%) 172.33M -59.6M (-25.7%) 0.83% -0.142 pp 0.03% -0.010 pp USD212.77 +17.9% 7 qtrs —
26 LEGAL & GENERAL GROUP PLC 673.2K -16.3K (-2.4%) 168.90M -29.1M (-14.7%) 0.81% -0.016 pp 0.04% -0.007 pp USD208.87 +20.1% 7 qtrs —
27 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 640.6K -10.4K (-1.6%) 160.70M -26.2M (-14.0%) 0.77% -0.009 pp 0.03% -0.005 pp USD210.46 +19.2% 7 qtrs —
28 LORD, ABBETT & CO. LLC 632.3K -96.6K (-13.3%) 158.62M -50.6M (-24.2%) 0.76% -0.112 pp 0.49% -0.136 pp USD213.74 +17.4% 7 qtrs —
29 BECK MACK & OLIVER LLC 627.0K +16.2K (+2.7%) 157.31M -18.0M (-10.3%) 0.75% +0.023 pp 2.86% -0.332 pp USD205.48 +22.1% 7 qtrs —
30 GOLDMAN SACHS GROUP INC 595.5K +173.4K (+41.1%) 149.40M +28.2M (+23.3%) 0.72% +0.210 pp 0.02% +0.004 pp USD238.70 +5.1% 6 qtrs —
31 THRIVENT FINANCIAL FOR LUTHERANS 577.0K +14.0K (+2.5%) 144.77M -16.9M (-10.4%) 0.69% +0.020 pp 0.26% -0.061 pp USD222.24 +12.9% 7 qtrs —
32 BANK OF NEW YORK MELLON CORP 573.9K -1.2M (-67.6%) 143.99M -364.5M (-71.7%) 0.69% -1.431 pp 0.03% -0.073 pp USD205.64 +22.0% 7 qtrs —
33 MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 570.1K -25.0K (-4.2%) 143.02M -27.8M (-16.3%) 0.69% -0.027 pp 0.05% -0.007 pp USD209.49 +19.8% 7 qtrs —
34 MADISON ASSET MANAGEMENT, LLC 525.9K -30.2K (-5.4%) 131.93M -27.7M (-17.4%) 0.63% -0.033 pp 1.52% -0.244 pp USD209.97 +19.5% 7 qtrs —
35 UBS GROUP AG 495.5K +10.5K (+2.2%) 124.32M -14.9M (-10.7%) 0.60% +0.015 pp 0.02% -0.002 pp USD214.91 +16.7% 7 qtrs —
36 LAZARD ASSET MANAGEMENT LLC 491.9K +8.4K (+1.7%) 123.40M -15.4M (-11.1%) 0.59% +0.012 pp 0.21% +0.022 pp USD246.60 +1.7% 7 qtrs —
37 RIVER ROAD ASSET MANAGEMENT, LLC 408.3K +48.3K (+13.4%) 102.42M -913.2K (-0.9%) 0.49% +0.060 pp 1.12% -0.034 pp USD241.32 +4.0% 7 qtrs —
38 WOODLINE PARTNERS LP 405.0K +117.9K (+41.1%) 101.62M +19.2M (+23.3%) 0.49% +0.143 pp 0.39% +0.006 pp USD273.37 -8.2% 6 qtrs —
39 BESSEMER GROUP INC 393.2K +209.9K (+114.6%) 98.64M +46.0M (+87.5%) 0.47% +0.254 pp 0.15% +0.071 pp USD267.04 -6.1% 7 qtrs —
40 HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC 368.9K -7.9K (-2.1%) 92.56M -15.6M (-14.4%) 0.44% -0.008 pp 0.28% -0.058 pp USD203.46 +23.3% 7 qtrs —
41 NATIXIS ADVISORS, L.P. 364.4K -17.8K (-4.7%) 91.42M -18.3M (-16.7%) 0.44% -0.019 pp 0.13% -0.031 pp USD225.82 +11.1% 7 qtrs —
42 ARIEL INVESTMENTS, LLC 360.1K -2.8K (-0.8%) 90.34M -13.8M (-13.3%) 0.43% -0.001 pp 0.98% -0.138 pp USD203.13 +23.5% 7 qtrs —
43 DEUTSCHE BANK AG\ 348.0K -4.7K (-1.3%) 87.31M -13.9M (-13.8%) 0.42% -0.004 pp 0.03% -0.006 pp USD213.83 +17.3% 7 qtrs —
44 EARNEST PARTNERS LLC 320.9K -2.8K (-0.8%) 80.52M -12.4M (-13.3%) 0.39% -0.001 pp 0.35% -0.058 pp USD204.75 +22.5% 7 qtrs —
45 PACER ADVISORS, INC. 313.7K +8.0K (+2.6%) 78.70M -9.1M (-10.3%) 0.38% +0.011 pp 0.20% -0.020 pp USD284.82 -11.9% 7 qtrs —
46 WELLS FARGO & COMPANY/MN 303.4K -9.5K (-3.0%) 76.13M -13.7M (-15.2%) 0.36% -0.010 pp 0.01% -0.003 pp USD204.96 +22.4% 7 qtrs —
47 MILLENNIUM MANAGEMENT LLC 277.3K +266.6K (+2,491.3%) 69.57M +66.5M (+2,164.7%) 0.33% +0.321 pp 0.03% +0.028 pp USD249.97 +0.4% 7 qtrs —
48 GLENMEDE TRUST CO NA 266.2K +266.2K (+100.0%) 66.79M +66.8M (+100.0%) 0.32% +0.320 pp 0.32% +0.317 pp USD250.88 +0.0% 1 qtrs NEW
49 BNP PARIBAS ARBITRAGE, SNC 253.4K +140.9K (+125.2%) 63.56M +31.3M (+96.8%) 0.30% +0.170 pp 0.03% +0.012 pp USD234.87 +6.8% 7 qtrs —
50 ENVESTNET ASSET MANAGEMENT INC 244.1K -17.7K (-6.8%) 61.24M -13.9M (-18.5%) 0.29% -0.020 pp 0.02% -0.004 pp USD204.88 +22.5% 7 qtrs —
51 ALLIANZ ASSET MANAGEMENT GMBH 242.6K +27.0K (+12.5%) 60.86M -1.0M (-1.6%) 0.29% +0.034 pp 0.06% -0.008 pp USD235.42 +6.6% 7 qtrs —
52 AMUNDI 239.8K -4.7K (-1.9%) 60.17M -7.1M (-10.5%) 0.29% -0.005 pp 0.02% -0.005 pp USD223.62 +12.2% 7 qtrs —
53 AMERIPRISE FINANCIAL INC 236.7K -22.1K (-8.6%) 59.38M -14.9M (-20.1%) 0.28% -0.025 pp 0.01% -0.004 pp USD218.15 +15.0% 7 qtrs —
54 FAIRVIEW CAPITAL INVESTMENT MANAGEMENT, LLC 232.0K -934.0 (-0.4%) 58.21M -8.7M (-13.0%) 0.28% 0.000 pp 2.99% -0.405 pp USD205.90 +21.8% 7 qtrs —
55 SWISS NATIONAL BANK 228.0K -13.3K (-5.5%) 57.21M -12.1M (-17.4%) 0.27% -0.015 pp 0.03% -0.006 pp USD207.28 +21.0% 7 qtrs —
56 BRANDES INVESTMENT PARTNERS, LP 222.9K -352.0 (-0.2%) 55.93M -8.2M (-12.7%) 0.27% +0.001 pp 0.43% -0.088 pp USD212.85 +17.9% 7 qtrs —
57 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 213.4K -34.8K (-14.0%) 53.55M -17.7M (-24.9%) 0.26% -0.041 pp 0.03% -0.012 pp USD203.20 +23.5% 7 qtrs —
58 SEI INVESTMENTS CO 213.2K +48.6K (+29.6%) 53.49M +6.2M (+13.2%) 0.26% +0.060 pp 0.05% +0.002 pp USD224.13 +11.9% 7 qtrs —
59 BARTLETT & CO. WEALTH MANAGEMENT LLC 207.0K -1.2K (-0.6%) 51.92M -7.8M (-13.1%) 0.25% 0.000 pp 0.68% -0.111 pp USD203.89 +23.0% 7 qtrs —
60 NUVEEN, LLC 205.6K -19.5K (-8.7%) 51.58M -13.0M (-20.2%) 0.25% -0.022 pp 0.01% -0.004 pp USD235.35 +6.6% 4 qtrs —
61 SQUAREPOINT OPS LLC 201.8K +176.0K (+680.6%) 50.64M +43.2M (+582.2%) 0.24% +0.212 pp 0.05% +0.046 pp USD252.02 -0.5% 7 qtrs —
62 BARCLAYS PLC 201.3K -419.4K (-67.6%) 50.51M -88.2M (-63.6%) 0.24% -0.501 pp 0.01% -0.024 pp USD250.99 0.0% 7 qtrs —
63 BANK OF MONTREAL /CAN/ 197.4K +96.2K (+95.1%) 49.52M +20.5M (+70.5%) 0.24% +0.116 pp 0.02% +0.006 pp USD229.87 +9.1% 7 qtrs —
64 CAMBIAR INVESTORS LLC 195.3K -2.6K (-1.3%) 49.00M -7.8M (-13.7%) 0.24% -0.002 pp 2.19% -0.393 pp USD203.13 +23.5% 7 qtrs —
65 QUBE RESEARCH & TECHNOLOGIES LTD 193.8K +182.5K (+1,615.6%) 48.62M +45.4M (+1,399.3%) 0.23% +0.220 pp 0.05% +0.046 pp USD252.99 -0.8% 7 qtrs —
66 FIRST TRUST ADVISORS LP 192.8K +4.6K (+2.4%) 48.37M -5.7M (-10.5%) 0.23% +0.007 pp 0.04% -0.005 pp USD262.83 -4.5% 7 qtrs —
67 HSBC HOLDINGS PLC 189.5K +47.9K (+33.8%) 47.61M +7.0M (+17.3%) 0.23% +0.058 pp 0.02% +0.002 pp USD215.43 +16.5% 7 qtrs —
68 ALYESKA INVESTMENT GROUP, L.P. 185.0K +181.7K (+5,571.4%) 46.41M +45.5M (+4,856.6%) 0.22% +0.219 pp 0.13% +0.128 pp USD250.15 +0.3% 7 qtrs —
69 SUMITOMO MITSUI TRUST HOLDINGS, INC. 182.6K -28.7K (-13.6%) 45.80M -14.8M (-24.5%) 0.22% -0.033 pp 0.03% -0.008 pp USD210.21 +19.3% 7 qtrs —
70 MARSHALL WACE, LLP 179.6K -444.0K (-71.2%) 45.05M -133.9M (-74.8%) 0.22% -0.531 pp 0.04% -0.141 pp USD270.05 -7.1% 7 qtrs —
71 AMI ASSET MANAGEMENT CORP 178.8K -4.0K (-2.2%) 44.85M -7.6M (-14.5%) 0.22% -0.004 pp 2.54% -0.387 pp USD203.13 +23.5% 7 qtrs —
72 MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. 177.3K +8.7K (+5.2%) 44.63M -3.8M (-7.8%) 0.21% +0.012 pp 0.03% -0.005 pp USD218.80 +14.7% 7 qtrs —
73 NATIONAL PENSION SERVICE 170.7K +6.3K (+3.8%) 42.83M -4.4M (-9.3%) 0.21% +0.009 pp 0.03% -0.005 pp USD209.32 +19.9% 7 qtrs —
74 GOTHAM ASSET MANAGEMENT, LLC 161.7K +66.7K (+70.1%) 40.56M +13.3M (+48.7%) 0.19% +0.081 pp 0.15% +0.029 pp USD249.67 +0.5% 5 qtrs —
75 DAVIDSON INVESTMENT ADVISORS 159.5K -636.0 (-0.4%) 40.01M -6.0M (-13.0%) 0.19% +0.000 pp 1.66% -0.286 pp USD204.39 +22.7% 7 qtrs —
76 SPEARS ABACUS ADVISORS LLC 158.6K -1.0K (-0.6%) 39.78M -6.0M (-13.2%) 0.19% -0.001 pp 0.74% -0.120 pp USD207.80 +20.7% 7 qtrs —
77 RHUMBLINE ADVISERS 152.6K -1.5K (-1.0%) 38.29M -6.0M (-13.5%) 0.18% -0.001 pp 0.03% -0.005 pp USD205.50 +22.1% 7 qtrs —
78 CITADEL ADVISORS LLC 148.3K -368.3K (-71.3%) 37.20M -111.1M (-74.9%) 0.18% -0.440 pp 0.01% -0.017 pp USD280.24 -10.5% 6 qtrs —
79 ADAGE CAPITAL PARTNERS GP, L.L.C. 147.0K +123.3K (+520.3%) 36.88M +30.1M (+442.1%) 0.18% +0.148 pp 0.06% +0.045 pp USD247.62 +1.3% 7 qtrs —
80 JANUS HENDERSON GROUP PLC 129.1K +164.0 (+0.1%) 32.39M -4.6M (-12.5%) 0.16% +0.001 pp 0.01% -0.002 pp USD203.30 +23.4% 7 qtrs —
81 SEQUOIA FINANCIAL ADVISORS, LLC 127.6K -16.5K (-11.4%) 32.02M -9.3M (-22.6%) 0.15% -0.019 pp 0.18% -0.073 pp USD205.63 +22.0% 7 qtrs —
82 CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 123.5K -4.3K (-3.4%) 30.97M -5.7M (-15.5%) 0.15% -0.004 pp 0.03% -0.007 pp USD203.58 +23.2% 7 qtrs —
83 PRICE T ROWE ASSOCIATES INC /MD/ 120.1K -61.0 (-0.1%) 30.14M -4.4M (-12.6%) 0.14% +0.000 pp 0.00% 0.000 pp USD215.74 +16.3% 7 qtrs —
84 QUANTINNO CAPITAL MANAGEMENT LP 118.4K +91.5K (+340.6%) 29.70M +22.0M (+285.0%) 0.14% +0.110 pp 0.06% +0.039 pp USD251.19 -0.1% 7 qtrs —
85 MONDRIAN INVESTMENT PARTNERS LTD 117.2K -144.8K (-55.3%) 29.39M -45.8M (-60.9%) 0.14% -0.173 pp 0.49% -0.771 pp USD287.06 -12.6% 2 qtrs —
86 RAYMOND JAMES FINANCIAL INC 117.1K -15.6K (-11.7%) 29.38M -8.7M (-22.9%) 0.14% -0.018 pp 0.01% -0.003 pp USD231.07 +8.6% 5 qtrs —
87 KBC GROUP NV 113.6K +7.2K (+6.7%) 28.51M -2.1M (-6.7%) 0.14% +0.009 pp 0.07% -0.008 pp USD209.60 +19.7% 7 qtrs —
88 WEDGE CAPITAL MANAGEMENT L L P/NC 110.7K +14.9K (+15.5%) 27.77M +270.7K (+1.0%) 0.13% +0.019 pp 0.50% +0.033 pp USD211.96 +18.4% 7 qtrs —
89 STIFEL FINANCIAL CORP 108.3K -10.0K (-8.5%) 27.16M -6.8M (-20.0%) 0.13% -0.011 pp 0.02% -0.007 pp USD204.03 +23.0% 7 qtrs —
90 WS MANAGEMENT LLLP 105.0K +— (+0.0%) 26.34M -3.8M (-12.6%) 0.13% +0.001 pp 2.16% -1.122 pp USD234.16 +7.1% 4 qtrs —
91 CLIFFORD SWAN INVESTMENT COUNSEL LLC 104.4K -1.9K (-1.8%) 26.18M -4.3M (-14.1%) 0.13% -0.002 pp 0.87% -0.146 pp USD226.06 +11.0% 6 qtrs —
92 WEITZ INVESTMENT MANAGEMENT, INC. 99.8K -40.0K (-28.6%) 25.03M -15.1M (-37.6%) 0.12% -0.047 pp 1.48% -0.693 pp USD203.13 +23.5% 7 qtrs —
93 CITIGROUP INC 98.5K +33.7K (+51.9%) 24.71M +6.1M (+32.8%) 0.12% +0.041 pp 0.01% +0.003 pp USD229.73 +9.2% 7 qtrs —
94 RUSSELL INVESTMENTS GROUP, LTD. 96.6K +11.1K (+12.9%) 24.27M -257.1K (-1.0%) 0.12% +0.014 pp 0.03% -0.001 pp USD234.81 +6.8% 7 qtrs —
95 HUNTER PERKINS CAPITAL MANAGEMENT, LLC 96.1K -8.5K (-8.1%) 24.11M -5.9M (-19.7%) 0.12% -0.010 pp 5.58% -1.080 pp USD203.40 +23.3% 7 qtrs —
96 UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH 95.3K -20.2K (-17.5%) 24.01M -9.2M (-27.6%) 0.11% -0.024 pp 0.04% -0.016 pp USD230.17 +9.0% 5 qtrs —
97 PRINCIPAL FINANCIAL GROUP INC 92.5K +2.0K (+2.2%) 23.20M -2.8M (-10.7%) 0.11% +0.003 pp 0.01% -0.001 pp USD204.82 +22.5% 7 qtrs —
98 PEAPACK GLADSTONE FINANCIAL CORP 88.4K +1.5K (+1.7%) 22.18M -2.8M (-11.1%) 0.11% +0.002 pp 0.28% -0.046 pp USD204.79 +22.5% 7 qtrs —
99 STRS OHIO 86.0K +4.0K (+4.9%) 21.58M -2.0M (-8.3%) 0.10% +0.005 pp 0.08% -0.006 pp USD233.72 +7.3% 7 qtrs —
100 ZACKS INVESTMENT MANAGEMENT 85.6K +1.9K (+2.3%) 21.48M -2.5M (-10.6%) 0.10% +0.003 pp 0.17% -0.023 pp USD209.82 +19.6% 7 qtrs —
Ownership breakdown by holder

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.81
Neutral
Ratio by volume
2.19
Bullish
Buys
81
Sells
100
Shares acquired
125.0K
Shares disposed
57.1K
Cash buys
—
Cash sales
8.00
Net activity
+67,937
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-03-27 Wilkinson Peter J Officer S-Sale D Common Stock 1,633 267.05 436.1K 1,852 D ↗
2026-03-27 Meltzer Jonathan C Officer S-Sale D Common Stock 839 267.05 224.1K 3,620 D ↗
2026-03-26 van der Vaart Sandra D Officer F-InKind D Common Stock 2,722 268.38 730.5K 6,239 D ↗
2026-03-26 Wilkinson Peter J Officer F-InKind D Common Stock 755 268.38 202.6K 3,485 D ↗
2026-03-26 Vaughn Bryan T Officer F-InKind D Common Stock 451 268.38 121.0K 6,746 D ↗
2026-03-26 Summy Amy B. Officer F-InKind D Common Stock 1,836 268.38 492.7K 7,880 D ↗
2026-03-26 Schroeder Mark S Officer F-InKind D Common Stock 4,600 268.38 1.23M 11,177 D ↗
2026-03-26 Schechter Adam H Director / Officer A-Award A Common Stock 58,470 0.00 — 139,243 D ↗
2026-03-26 Oyegunwa Akinbolade Officer F-InKind D Common Stock 382 268.38 102.5K 5,064 D ↗
2026-03-26 Meltzer Jonathan C Officer F-InKind D Common Stock 711 268.38 190.8K 4,459 D ↗
2026-03-26 Kyle Kathryn W Officer F-InKind D Common Stock 451 268.38 121.0K 4,575 D ↗
2026-03-26 GRAHAM ANITA Z Officer F-InKind D Common Stock 2,879 268.38 772.7K 5,185 D ↗
2026-03-26 Caveney Brian J Officer F-InKind D Common Stock 4,042 268.38 1.08M 35,369 D ↗
2026-03-26 Bailey Megan D. Officer F-InKind D Common Stock 481 268.38 129.1K 4,851 D ↗
2026-03-03 Schechter Adam H Director / Officer S-Sale D Common Stock 8,705 279.96 2.44M 80,773 D ↗
2026-02-27 van der Vaart Sandra D Officer S-Sale D Common Stock 548 284.91 156.0K 2,579 D ↗
2026-02-24 Caveney Brian J Officer S-Sale D Common Stock 1,500 286.31 429.5K 30,107 D ↗
2026-02-19 Wilkinson Peter J Officer S-Sale D Common Stock 666 277.94 185.1K 1,852 D ↗
2026-02-12 Meltzer Jonathan C Officer S-Sale D Common Stock 87 290.42 25.3K 2,782 D ↗
2026-02-11 van der Vaart Sandra D Officer F-InKind D Common Stock 99 289.89 28.7K 3,126 D ↗
2026-02-11 Wilkinson Peter J Officer M-Exempt A Common Stock 160 0.00 — 2,564 D ↗
2026-02-11 Wengel Kathryn E Director M-Exempt D Restricted Stock Unit 897 0.00 — 773 D ↗
2026-02-11 Wang Julia Aijun Officer M-Exempt D Restricted Stock Unit 860 0.00 — 4,964 D ↗
2026-02-11 Vaughn Bryan T Officer M-Exempt D Restricted Stock Unit 323 0.00 — 4,031 D ↗
2026-02-11 Summy Amy B. Officer M-Exempt A Common Stock 230 0.00 — 5,805 D ↗
2026-02-11 Schroeder Mark S Officer M-Exempt A Common Stock 806 0.00 — 6,732 D ↗
2026-02-11 Schechter Adam H Director / Officer S-Sale D Common Stock 5,273 284.38 1.50M 87,343 D ↗
2026-02-11 Rothman Paul Director M-Exempt A Common Stock 897 0.00 — 2,571 D ↗
2026-02-11 Parham Richelle P Director M-Exempt A Common Stock 897 0.00 — 3,366 D ↗
2026-02-11 Oyegunwa Akinbolade Officer M-Exempt D Restricted Stock Unit 230 0.00 — 2,190 D ↗
2026-02-11 NEUPERT PETER M Director M-Exempt A Common Stock 897 0.00 — 13,784 D ↗
2026-02-11 Meltzer Jonathan C Officer M-Exempt D Restricted Stock Unit 243 0.00 — 2,694 D ↗
2026-02-11 Kyle Kathryn W Officer M-Exempt A Common Stock 216 0.00 — 3,504 D ↗
2026-02-11 Kong Garheng Director M-Exempt A Common Stock 897 0.00 — 13,739 D ↗
2026-02-11 Kliphouse Kirsten Marie Director M-Exempt A Common Stock 897 0.00 — 3,160 D ↗
2026-02-11 GRAHAM ANITA Z Officer M-Exempt D Restricted Stock Unit 356 0.00 — 2,401 D ↗
2026-02-11 Davis Jeffrey A. Director M-Exempt A Common Stock 897 0.00 — 5,460 D ↗
2026-02-11 Caveney Brian J Officer M-Exempt A Common Stock 740 0.00 — 31,818 D ↗
2026-02-11 Bailey Megan D. Officer M-Exempt A Common Stock 403 0.00 — 4,286 D ↗
2026-02-11 ANDERSON KERRII B Director M-Exempt A Common Stock 897 0.00 — 9,563 D ↗
2026-02-10 Wilkinson Peter J Officer A-Award A Non-qualified Stock Options 1,300 284.50 369.9K 1,300 D ↗
2026-02-10 Wengel Kathryn E Director A-Award A Restricted Stock Unit 773 0.00 — 1,670 D ↗
2026-02-10 Wang Julia Aijun Officer A-Award A Non-qualified Stock Options 7,100 284.50 2.02M 7,100 D ↗
2026-02-10 Vaughn Bryan T Officer A-Award A Restricted Stock Unit 730 0.00 — 4,354 D ↗
2026-02-10 Summy Amy B. Officer A-Award A Restricted Stock Unit 620 0.00 — 1,534 D ↗
2026-02-10 Schechter Adam H Director / Officer A-Award A Non-qualified Stock Options 31,700 284.50 9.02M 31,700 D ↗
2026-02-10 Sampson John H Director A-Award A Restricted Stock Unit 773 0.00 — 773 D ↗
2026-02-10 Rothman Paul Director A-Award A Restricted Stock Unit 733 0.00 — 1,670 D ↗
2026-02-10 Parham Richelle P Director A-Award A Restricted Stock Unit 773 0.00 — 1,670 D ↗
2026-02-10 Oyegunwa Akinbolade Officer A-Award A Restricted Stock Unit 810 0.00 — 2,420 D ↗
2026-02-10 NEUPERT PETER M Director A-Award A Restricted Stock Unit 773 0.00 — 1,670 D ↗
2026-02-10 Meltzer Jonathan C Officer S-Sale D Common Stock 91 276.79 25.2K 2,696 D ↗
2026-02-10 Kyle Kathryn W Officer A-Award A Non-qualified Stock Options 2,700 284.50 768.2K 2,700 D ↗
2026-02-10 Kong Garheng Director A-Award A Restricted Stock Unit 773 0.00 — 1,670 D ↗
2026-02-10 Kliphouse Kirsten Marie Director A-Award A Restricted Stock Unit 773 0.00 — 1,670 D ↗
2026-02-10 GRAHAM ANITA Z Officer A-Award A Non-qualified Stock Options 4,100 284.50 1.17M 4,100 D ↗
2026-02-10 Davis Jeffrey A. Director A-Award A Restricted Stock Unit 773 0.00 — 1,670 D ↗
2026-02-10 Caveney Brian J Officer A-Award A Restricted Stock Unit 2,020 0.00 — 4,910 D ↗
2026-02-10 Bulto Carulla Victor Director A-Award A Restricted Stock Unit 773 0.00 — 909 D ↗
2026-02-10 Bailey Megan D. Officer A-Award A Restricted Stock Unit 1,100 0.00 — 3,230 D ↗
2026-02-10 ANDERSON KERRII B Director A-Award A Restricted Stock Unit 773 0.00 — 1,670 D ↗
2026-02-09 van der Vaart Sandra D Officer F-InKind D Common Stock 93 274.01 25.5K 2,849 D ↗
2026-02-09 Wilkinson Peter J Officer F-InKind D Common Stock 46 274.01 12.6K 2,028 D ↗
2026-02-09 Vaughn Bryan T Officer F-InKind D Common Stock 61 274.01 16.7K 5,383 D ↗
2026-02-09 Summy Amy B. Officer F-InKind D Common Stock 80 274.01 21.9K 5,575 D ↗
2026-02-09 Schroeder Mark S Officer F-InKind D Common Stock 166 274.01 45.5K 5,979 D ↗
2026-02-09 Schechter Adam H Director / Officer F-InKind D Common Stock 1,352 274.01 370.5K 92,616 D ↗
2026-02-09 Sampson John H Director — — — 0 0.00 — 0 — ↗
2026-02-09 Oyegunwa Akinbolade Officer F-InKind D Common Stock 51 274.01 14.0K 3,944 D ↗
2026-02-09 Meltzer Jonathan C Officer S-Sale D Common Stock 88 275.53 24.2K 2,869 D ↗
2026-02-09 Kyle Kathryn W Officer F-InKind D Common Stock 61 274.01 16.7K 3,288 D ↗
2026-02-09 GRAHAM ANITA Z Officer F-InKind D Common Stock 112 274.01 30.7K 1,213 D ↗
2026-02-09 Caveney Brian J Officer F-InKind D Common Stock 32 274.01 8.8K 31,078 D ↗
2026-02-09 Bailey Megan D. Officer F-InKind D Common Stock 85 274.01 23.3K 3,906 D ↗
2026-02-07 van der Vaart Sandra D Officer M-Exempt A Common Stock 353 0.00 — 2,942 D ↗
2026-02-07 Wilkinson Peter J Officer M-Exempt D Restricted Stock Unit 134 0.00 — 2,224 D ↗
2026-02-07 Vaughn Bryan T Officer M-Exempt D Restricted Stock Unit 178 0.00 — 3,624 D ↗
2026-02-07 Summy Amy B. Officer M-Exempt D Restricted Stock Unit 222 0.00 — 914 D ↗
2026-02-07 Schroeder Mark S Officer M-Exempt D Restricted Stock Unit 517 0.00 — 3,328 D ↗
2026-02-07 Schechter Adam H Director / Officer M-Exempt A Common Stock 3,249 0.00 — 93,968 D ↗
2026-02-07 Oyegunwa Akinbolade Officer M-Exempt D Restricted Stock Unit 149 0.00 — 1,610 D ↗
2026-02-07 Meltzer Jonathan C Officer M-Exempt A Common Stock 263 0.00 — 2,957 D ↗
2026-02-07 Kyle Kathryn W Officer M-Exempt A Common Stock 178 0.00 — 3,349 D ↗
2026-02-07 GRAHAM ANITA Z Officer M-Exempt D Restricted Stock Unit 367 0.00 — 1,397 D ↗
2026-02-07 Caveney Brian J Officer M-Exempt D Restricted Stock Unit 517 0.00 — 3,001 D ↗
2026-02-07 Bailey Megan D. Officer M-Exempt D Restricted Stock Unit 67 0.00 — 2,130 D ↗
2026-02-06 van der Vaart Sandra D Officer M-Exempt A Common Stock 387 0.00 — 2,690 D ↗
2026-02-06 Wilkinson Peter J Officer F-InKind D Common Stock 45 277.20 12.5K 1,940 D ↗
2026-02-06 Wang Julia Aijun Officer F-InKind D Common Stock 254 277.20 70.4K 1,202 D ↗
2026-02-06 Vaughn Bryan T Officer M-Exempt A Common Stock 180 0.00 — 5,327 D ↗
2026-02-06 Summy Amy B. Officer M-Exempt A Common Stock 223 0.00 — 5,525 D ↗
2026-02-06 Schroeder Mark S Officer F-InKind D Common Stock 239 277.20 66.3K 5,464 D ↗
2026-02-06 Schechter Adam H Director / Officer M-Exempt D Restricted Stock Unit 4,460 0.00 — 18,679 D ↗
2026-02-06 Oyegunwa Akinbolade Officer M-Exempt A Common Stock 180 0.00 — 3,907 D ↗
2026-02-06 Meltzer Jonathan C Officer M-Exempt A Common Stock 267 0.00 — 2,785 D ↗
2026-02-06 Kyle Kathryn W Officer M-Exempt D Restricted Stock Unit 180 0.00 — 1,778 D ↗
2026-02-06 GRAHAM ANITA Z Officer M-Exempt A Common Stock 327 0.00 — 1,077 D ↗
2026-02-06 Caveney Brian J Officer M-Exempt D Restricted Stock Unit 670 0.00 — 3,518 D ↗
2026-02-06 Bailey Megan D. Officer M-Exempt A Common Stock 180 0.00 — 3,774 D ↗
2026-01-04 Vaughn Bryan T Officer — — Restricted Stock Unit 1,320 0.00 — 0 D ↗
2026-01-04 Meltzer Jonathan C Officer — — Common Stock 0 0.00 — 2,518 D ↗
2026-01-04 Kyle Kathryn W Officer — — Restricted Stock Unit 770 0.00 — 0 D ↗
2025-12-01 Bulto Carulla Victor Director A-Award A Restricted Stock Unit 136 0.00 — 136 D ↗
2025-11-11 Schechter Adam H Director / Officer S-Sale D Common Stock 5,745 262.75 1.51M 87,574 D ↗
2025-11-03 Oyegunwa Akinbolade Officer F-InKind D Common Stock 107 257.84 27.6K 3,727 D ↗
2025-11-03 Bailey Megan D. Officer F-InKind D Common Stock 179 257.84 46.2K 3,594 D ↗
2025-11-01 Oyegunwa Akinbolade Officer M-Exempt D Restricted Stock Unit 370 0.00 — 1,939 D ↗
2025-11-01 Bailey Megan D. Officer M-Exempt D Restricted Stock Unit 370 0.00 — 2,599 D ↗
2025-10-31 Parham Richelle P Director S-Sale D Common Stock 7,009 254.28 1.78M 2,469 D ↗
2025-08-13 van der Vaart Sandra D Officer M-Exempt A Common Stock 3,903 131.43 513.0K 6,177 D ↗
2025-08-11 Schechter Adam H Director / Officer S-Sale D Common Stock 5,643 266.78 1.51M 93,319 D ↗
2025-07-30 Gilliland Dwight Gary Director S-Sale D Common Stock 2,000 264.95 529.9K 6,656 D ↗
2025-07-29 Wilkinson Peter J Officer S-Sale D Common Stock 100 261.04 26.1K 1,852 D ↗
2025-07-24 ANDERSON KERRII B Director S-Sale D Common Stock 3,500 280.00 980.0K 8,666 D ↗
2025-07-01 ANDERSON KERRII B Director S-Sale D Common Stock 500 265.00 132.5K 12,166 D ↗
2025-06-11 ANDERSON KERRII B Director S-Sale D Common Stock 500 260.00 130.0K 12,666 D ↗
2025-06-03 Caveney Brian J Officer S-Sale D Common Stock 2,000 247.00 494.0K 30,067 D ↗
2025-05-12 Schechter Adam H Director / Officer S-Sale D Common Stock 6,105 248.73 1.52M 98,962 D ↗
2025-05-01 van der Vaart Sandra D Officer S-Sale D Common Stock 1,900 238.36 452.9K 2,244 D ↗
2025-05-01 Wilkinson Peter J Officer S-Sale D Common Stock 829 242.27 200.8K 2,054 D ↗
2025-04-01 Bailey Megan D. Officer F-InKind D Common Stock 68 232.65 15.8K 3,403 D ↗
2025-03-28 Summy Amy B. Officer S-Sale D Common Stock 758 231.67 175.6K 5,302 D ↗
2025-03-28 Schroeder Mark S Officer S-Sale D Common Stock 2,635 231.67 610.5K 4,960 D ↗
2025-03-27 van der Vaart Sandra D Officer F-InKind D Common Stock 1,352 231.67 313.2K 4,144 D ↗
2025-03-27 Wilkinson Peter J Officer F-InKind D Common Stock 359 231.67 83.2K 2,883 D ↗
2025-03-27 Summy Amy B. Officer F-InKind D Common Stock 562 231.67 130.2K 6,060 D ↗
2025-03-27 Schroeder Mark S Officer A-Award A Common Stock 4,840 0.00 — 9,800 D ↗
2025-03-27 Schechter Adam H Director / Officer F-InKind D Common Stock 13,584 231.67 3.15M 105,067 D ↗
2025-03-27 Oyegunwa Akinbolade Officer F-InKind D Common Stock 198 231.67 45.9K 3,464 D ↗
2025-03-27 EISENBERG GLENN A Officer A-Award A Common Stock 8,305 0.00 — 41,550 D ↗
2025-03-27 Caveney Brian J Officer F-InKind D Common Stock 2,109 231.67 488.6K 32,067 D ↗
2025-03-27 BERBERIAN LANCE Officer F-InKind D Common Stock 1,353 231.67 313.4K 18,652 D ↗
2025-03-05 ANDERSON KERRII B Director S-Sale D Common Stock 500 255.63 127.8K 13,166 D ↗
2025-02-28 Schroeder Mark S Officer M-Exempt D Non-qualified Stock Options 3,903 131.43 513.0K 0 D ↗
2025-02-25 van der Vaart Sandra D Officer S-Sale D Common Stock 1,314 251.30 330.2K 2,171 D ↗
2025-02-24 Summy Amy B. Officer S-Sale D Common Stock 226 250.40 56.6K 4,545 D ↗
2025-02-18 Wilkinson Peter J Officer M-Exempt A Common Stock 1,413 163.63 231.2K 3,406 D ↗
2025-02-11 van der Vaart Sandra D Officer A-Award A Restricted Stock Unit 1,130 0.00 — 2,580 D ↗
2025-02-11 Wilkinson Peter J Officer A-Award A Restricted Stock Unit 1,610 0.00 — 2,614 D ↗
2025-02-11 Wengel Kathryn E Director A-Award A Restricted Stock Unit 897 0.00 — 897 D ↗
2025-02-11 Wang Julia Aijun Officer A-Award A Non-qualified Stock Options 7,800 245.14 1.91M 7,800 D ↗
2025-02-11 Summy Amy B. Officer M-Exempt A Common Stock 201 0.00 — 4,826 D ↗
2025-02-11 Schroeder Mark S Officer M-Exempt A Common Stock 473 0.00 — 6,530 D ↗
2025-02-11 Schechter Adam H Director / Officer M-Exempt A Common Stock 2,963 0.00 — 89,408 D ↗
2025-02-11 Rothman Paul Director A-Award A Restricted Stock Unit 897 0.00 — 897 D ↗
2025-02-11 Parham Richelle P Director A-Award A Restricted Stock Unit 897 0.00 — 897 D ↗
2025-02-11 Oyegunwa Akinbolade Officer F-InKind D Common Stock 42 245.14 10.3K 2,974 D ↗
2025-02-11 NEUPERT PETER M Director A-Award A Restricted Stock Unit 897 0.00 — 897 D ↗
2025-02-11 Kong Garheng Director A-Award A Restricted Stock Unit 897 0.00 — 897 D ↗
2025-02-11 Kliphouse Kirsten Marie Director A-Award A Restricted Stock Unit 897 0.00 — 897 D ↗
2025-02-11 Gilliland Dwight Gary Director A-Award A Restricted Stock Unit 897 0.00 — 897 D ↗
2025-02-11 GRAHAM ANITA Z Officer A-Award A Restricted Stock Unit 1,070 0.00 — 2,091 D ↗
2025-02-11 EISENBERG GLENN A Officer F-InKind D Common Stock 213 245.14 52.2K 33,245 D ↗
2025-02-11 Davis Jeffrey A. Director A-Award A Restricted Stock Unit 897 0.00 — 897 D ↗
2025-02-11 Caveney Brian J Officer A-Award A Restricted Stock Unit 2,220 0.00 — 4,661 D ↗
2025-02-11 Bailey Megan D. Officer A-Award A Non-qualified Stock Options 3,700 245.14 907.0K 3,700 D ↗
2025-02-11 BERBERIAN LANCE Officer M-Exempt D Restricted Stock Unit 323 0.00 — 1,067 D ↗
2025-02-11 ANDERSON KERRII B Director A-Award A Restricted Stock Unit 897 0.00 — 897 D ↗
2025-02-07 van der Vaart Sandra D Officer M-Exempt A Common Stock 354 0.00 — 3,342 D ↗
2025-02-07 Wilkinson Peter J Officer M-Exempt A Common Stock 134 0.00 — 2,308 D ↗
2025-02-07 Summy Amy B. Officer F-InKind D Common Stock 68 246.27 16.7K 4,625 D ↗
2025-02-07 Schroeder Mark S Officer F-InKind D Common Stock 47 246.27 11.6K 6,057 D ↗
2025-02-07 Schechter Adam H Director / Officer M-Exempt A Common Stock 3,250 0.00 — 93,911 D ↗
2025-02-07 Oyegunwa Akinbolade Officer M-Exempt D Restricted Stock Unit 149 0.00 — 1,753 D ↗
2025-02-07 GRAHAM ANITA Z Officer M-Exempt D Restricted Stock Unit 369 0.00 — 1,021 D ↗
2025-02-07 EISENBERG GLENN A Officer F-InKind D Common Stock 234 246.27 57.6K 32,651 D ↗
2025-02-07 Caveney Brian J Officer F-InKind D Common Stock 149 246.27 36.7K 28,920 D ↗
2025-02-07 Bailey Megan D. Officer F-InKind D Common Stock 85 246.27 20.9K 685 D ↗
2025-02-07 BERBERIAN LANCE Officer M-Exempt A Common Stock 354 0.00 — 16,537 D ↗
2025-02-06 van der Vaart Sandra D Officer F-InKind D Common Stock 102 247.74 25.3K 2,988 D ↗
2025-02-06 Wilkinson Peter J Officer F-InKind D Common Stock 46 247.74 11.4K 2,174 D ↗
2025-02-06 Wengel Kathryn E Director M-Exempt A Common Stock 944 0.00 — 3,236 D ↗
2025-02-06 Wang Julia Aijun Officer M-Exempt D Restricted Stock Unit 893 0.00 — 1,787 D ↗
2025-02-06 Summy Amy B. Officer M-Exempt A Common Stock 223 0.00 — 4,542 D ↗
2025-02-06 Schroeder Mark S Officer F-InKind D Common Stock 210 247.74 52.0K 5,569 D ↗
2025-02-06 Schechter Adam H Director / Officer M-Exempt A Common Stock 4,460 0.00 — 91,901 D ↗
2025-02-06 Rothman Paul Director M-Exempt D Restricted Stock Unit 944 0.00 — 0 D ↗
2025-02-06 Parham Richelle P Director M-Exempt A Common Stock 944 0.00 — 9,478 D ↗
2025-02-06 Oyegunwa Akinbolade Officer M-Exempt A Common Stock 180 0.00 — 2,846 D ↗
2025-02-06 NEUPERT PETER M Director M-Exempt A Common Stock 944 0.00 — 12,887 D ↗
2025-02-06 Kong Garheng Director M-Exempt A Common Stock 944 0.00 — 12,842 D ↗
2025-02-06 Kliphouse Kirsten Marie Director M-Exempt D Restricted Stock Unit 944 0.00 — 0 D ↗
2025-02-06 Gilliland Dwight Gary Director M-Exempt D Restricted Stock Unit 944 0.00 — 0 D ↗
2025-02-06 GRAHAM ANITA Z Officer M-Exempt D Restricted Stock Unit 326 0.00 — 1,390 D ↗
2025-02-06 EISENBERG GLENN A Officer M-Exempt A Common Stock 966 0.00 — 32,255 D ↗
2025-02-06 Davis Jeffrey A. Director M-Exempt A Common Stock 944 0.00 — 4,563 D ↗
2025-02-06 Caveney Brian J Officer F-InKind D Common Stock 212 247.74 52.5K 28,552 D ↗
2025-02-06 Bailey Megan D. Officer M-Exempt A Common Stock 180 0.00 — 616 D ↗
2025-02-06 BERBERIAN LANCE Officer M-Exempt D Restricted Stock Unit 356 0.00 — 1,744 D ↗
2025-02-06 ANDERSON KERRII B Director M-Exempt D Restricted Stock Unit 944 0.00 — 0 D ↗
2025-01-07 ANDERSON KERRII B Director S-Sale D Common Stock 1,000 235.00 235.0K 12,722 D ↗
2024-12-02 Wang Julia Aijun Officer — — — 0 0.00 — 0 — ↗
2024-12-02 Gilliland Dwight Gary Director S-Sale D Common Stock 1,000 241.00 241.0K 7,712 D ↗
2024-12-02 EISENBERG GLENN A Officer M-Exempt A Common Stock 8,923 209.25 1.87M 40,212 D ↗
2024-11-22 Summy Amy B. Officer M-Exempt A Common Stock 4,015 168.52 676.6K 7,990 D ↗
2024-11-21 van der Vaart Sandra D Officer S-Sale D Common Stock 1,000 239.42 239.4K 2,670 D ↗
2024-11-11 Schechter Adam H Director / Officer S-Sale D Common Stock 6,189 243.47 1.51M 87,441 D ↗
2024-11-01 Oyegunwa Akinbolade Officer — — Restricted Stock Unit 540 0.00 — 0 D ↗
2024-11-01 Bailey Megan D. Officer A-Award A Restricted Stock Unit 1,110 0.00 — 6,517 D ↗
2024-10-24 ANDERSON KERRII B Director S-Sale D Common Stock 1,000 230.00 230.0K 13,722 D ↗

Executive team

Top executives
EBIT / Employee
21.9K
Shares Outstanding
82.30M

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2025 ADAM H. SCHECHTER President and Chief Executive Officer 1.44M — 11.40M 2.75M 2.06M 687.8K 18.34M 77.18% ↗
2 2025 JULIA A. WANG Executive Vice President and Chief Financial Officer 737.5K 200.0K 2.68M 649.1K 706.8K 40.3K 5.01M 66.41% ↗
3 2025 MARK S. SCHROEDER Former Executive Vice President and President, Diagnostics and Chief Operations Officer 748.5K — 2.51M 607.5K 727.4K 188.8K 4.79M 65.23% ↗
4 2025 BRIAN J. CAVENEY Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer 748.5K — 2.30M 557.6K 719.9K 25.5K 4.36M 65.70% ↗
5 2025 MEGAN D. BAILEY Executive Vice President and President, Central Laboratories and International 568.5K — 1.26M 307.9K 547.6K 34.8K 2.72M 57.63% ↗
6 2024 ADAM H. SCHECHTER President and Chief Executive Officer 1.42M — 12.16M 3.02M 2.11M 619.2K 19.33M 78.53% ↗
7 2024 GLENN A. EISENBERG Executive Vice President and Former Chief Financial Officer 830.5K — 2.63M 655.6K 826.4K 55.1K 5.00M 65.77% ↗
8 2024 MARK S. SCHROEDER Former Executive Vice President and President, Diagnostics and Chief Operations Officer 660.8K — 2.03M 502.7K 678.7K 116.7K 3.99M 63.47% ↗
9 2024 MARK S. SCHROEDER Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer 660.8K — 2.03M 502.7K 678.7K 116.7K 3.99M 63.47% ↗
10 2024 BRIAN J. CAVENEY Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer 660.8K — 1.83M 451.7K 604.0K 26.2K 3.57M 63.82% ↗
11 2024 JULIA A. WANG Executive Vice President and Chief Financial Officer 55.8K — 2.67M 638.1K — 133.00 3.36M 98.34% ↗
12 2024 ANITA Z. GRAHAM Executive Vice President and Chief Human Resources Officer 569.2K 500.0K 891.0K 218.5K 481.4K 25.4K 2.69M 41.31% ↗
13 2023 ADAM H. SCHECHTER President and Chief Executive Officer 1.37M — 9.07M 2.25M 2.35M 938.3K 15.98M 70.85% ↗
14 2023 PAUL R. KIRCHGRABER Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology 424.0K — 1.65M 410.6K — 2.85M 5.33M 38.64% ↗
15 2023 GLENN A. EISENBERG Executive Vice President and Chief Financial Officer 805.5K — 2.47M 615.9K 917.1K 144.6K 4.96M 62.33% ↗
16 2023 GLENN A. EISENBERG Executive Vice President and Former Chief Financial Officer 805.5K — 2.47M 615.9K 917.1K 144.6K 4.96M 62.33% ↗
17 2023 THOMAS H. PIKE Executive Vice President 528.8K — 4.13M — — 11.2K 4.67M 88.43% ↗
18 2023 MARK S. SCHROEDER Former Executive Vice President and President, Diagnostics and Chief Operations Officer 617.6K — 1.89M 461.6K 718.8K 104.3K 3.80M 62.04% ↗
19 2023 MARK S. SCHROEDER Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer 617.6K — 1.89M 461.6K 718.8K 104.3K 3.80M 62.04% ↗
20 2023 BRIAN J. CAVENEY Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer 617.6K — 1.75M 433.0K 609.7K 70.8K 3.48M 62.66% ↗
21 2023 BRIAN J. CAVENEY Executive Vice President and President, Early Development and Chief Medical and Scientific Officer 617.6K — 1.75M 433.0K 609.7K 70.8K 3.48M 62.66% ↗
22 2023 ANITA Z. GRAHAM Executive Vice President and Chief Human Resources Officer 420.0K 500.0K 1.01M 196.7K 405.3K 21.6K 2.56M 47.30% ↗
23 2022 ADAM H. SCHECHTER President and Chief Executive Officer 1.32M — 9.06M 2.14M 1.68M 729.2K 14.93M 75.07% ↗
24 2022 GLENN A. EISENBERG Executive Vice President and Former Chief Financial Officer 780.5K — 6.55M 587.0K 661.6K 101.9K 8.68M 82.22% ↗
25 2022 GLENN A. EISENBERG Executive Vice President and Chief Financial Officer 780.5K — 6.55M 587.0K 661.6K 101.9K 8.68M 82.22% ↗
26 2022 PAUL R. KIRCHGRABER Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology 630.0K — 1.65M 388.8K 267.0K 82.7K 3.02M 67.52% ↗
27 2022 BRIAN J. CAVENEY Executive Vice President, President, Diagnostics and Chief Medical Officer 538.0K — 1.44M 343.0K 641.8K 44.8K 3.01M 59.30% ↗
28 2022 BRIAN J. CAVENEY Executive Vice President and President, Early Development and Chief Medical and Scientific Officer 538.0K — 1.44M 343.0K 641.8K 44.8K 3.01M 59.30% ↗
29 2022 BRIAN J. CAVENEY Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer 538.0K — 1.44M 343.0K 641.8K 44.8K 3.01M 59.30% ↗
30 2022 MARK S. SCHROEDER Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer 538.0K — 1.44M 343.0K 456.1K 65.1K 2.84M 62.75% ↗
31 2022 MARK S. SCHROEDER Executive Vice President, and President, Diagnostics, Laboratory Operations and Global Supply Chain 538.0K — 1.44M 343.0K 456.1K 65.1K 2.84M 62.75% ↗
32 2021 ADAM H SCHECHTER Chief Executive Officer 1.28M — 13.24M 1.80M 3.80M 432.0K 20.55M 73.18% ↗
33 2021 ADAM H. SCHECHTER President and Chief Executive Officer 1.28M — 13.24M 1.80M 3.80M 432.0K 20.55M 73.18% ↗
34 2021 GLENN A. EISENBERG Executive Vice President and Chief Financial Officer 756.3K — 3.66M 497.5K 1.50M 43.7K 6.46M 64.38% ↗
35 2021 GLENN A. EISENBERG Executive Vice President Chief Financial Officer 756.3K — 3.66M 497.5K 1.50M 43.7K 6.46M 64.38% ↗
36 2021 PAUL R. KIRCHGRABER Executive Vice President, Chief Executive Officer, Drug Development 625.8K — 2.11M 286.0K 1.24M 155.4K 4.42M 54.24% ↗
37 2021 PAUL R. KIRCHGRABER Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology 625.8K — 2.11M 286.0K 1.24M 155.4K 4.42M 54.24% ↗
38 2021 MARK S. SCHROEDER Executive Vice President, and President, Diagnostics, Laboratory Operations and Global Supply Chain 521.5K — 2.11M 286.0K 1.03M 35.9K 3.99M 60.10% ↗
39 2021 MARK S. SCHROEDER Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer 521.5K — 2.11M 286.0K 1.03M 35.9K 3.99M 60.10% ↗
40 2021 MARK S. SCHROEDER Executive Vice President, Diagnostics, Laboratory Operations and Global Supply Chain 521.5K — 2.11M 286.0K 1.03M 35.9K 3.99M 60.10% ↗
41 2021 BRIAN J. CAVENEY Executive Vice President and President, Early Development and Chief Medical and Scientific Officer 521.5K — 2.12M 286.0K 1.03M 15.9K 3.98M 60.50% ↗
42 2021 BRIAN J. CAVENEY Executive Vice President, President, Diagnostics and Chief Medical Officer 521.5K — 2.11M 286.0K 1.03M 15.9K 3.97M 60.40% ↗
43 2021 BRIAN J. CAVENEY Executive Vice President, Diagnostics Chief Medical Officer 521.5K — 2.11M 286.0K 1.03M 15.9K 3.97M 60.40% ↗
44 2020 ADAM H SCHECHTER Chief Executive Officer 1.25M — 8.04M 1.83M 3.19M 433.3K 14.74M 66.95% ↗
45 2020 ADAM H. SCHECHTER President and Chief Executive Officer 1.25M — 8.04M 1.83M 3.19M 433.3K 14.74M 66.95% ↗
46 2020 ADAM H. SCHECHTER Chief Executive Officer 1.25M — 8.04M 1.83M 3.19M 433.3K 14.74M 66.95% ↗
47 2020 GLENN A. EISENBERG Executive Vice President and Chief Financial Officer 723.0K — 2.22M 504.4K 1.21M 45.3K 4.71M 57.92% ↗
48 2020 GLENN A. EISENBERG Executive Vice President Chief Financial Officer 723.0K — 2.22M 504.4K 1.21M 45.3K 4.71M 57.92% ↗
49 2020 MARK S. SCHROEDER Executive Vice President, Diagnostics, Laboratory Operations and Global Supply Chain 505.0K — 1.28M 292.2K 850.0K 61.5K 2.99M 52.67% ↗
50 2020 MARK S. SCHROEDER Executive Vice President, and President, Diagnostics, Laboratory Operations and Global Supply Chain 505.0K — 1.28M 292.2K 850.0K 61.5K 2.99M 52.67% ↗
51 2020 MARK S. SCHROEDER Executive Vice President, President Diagnostics, Laboratory Operations and Global Supply Chain 505.0K — 1.28M 292.2K 850.0K 61.5K 2.99M 52.67% ↗
52 2020 PAUL R. KIRCHGRABER Executive Vice President, Chief Executive Officer, Drug Development 606.0K — 1.28M 292.2K 724.6K 67.0K 2.97M 53.00% ↗
53 2020 PAUL R. KIRCHGRABER Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology 606.0K — 1.28M 292.2K 724.6K 67.0K 2.97M 53.00% ↗
54 2020 BRIAN J. CAVENEY Executive Vice President President, Diagnostics Chief Medical Officer 505.0K — 1.28M 292.2K 850.0K 10.0K 2.94M 53.59% ↗
55 2020 BRIAN J. CAVENEY Executive Vice President, President, Diagnostics and Chief Medical Officer 505.0K — 1.28M 292.2K 850.0K 10.0K 2.94M 53.59% ↗
56 2020 BRIAN J. CAVENEY Executive Vice President, Diagnostics Chief Medical Officer 505.0K — 1.28M 292.2K 850.0K 10.0K 2.94M 53.59% ↗
57 2019 DAVID P. KING Former Chief Executive Officer 1.22M — 7.68M 1.80M 1.85M 394.9K 12.93M 73.26% ↗
58 2019 GLENN A. EISENBERG Executive Vice President Chief Financial Officer 705.5K — 6.97M 399.1K 715.5K 35.7K 8.82M 83.49% ↗
59 2019 ADAM H. SCHECHTER Chief Executive Officer 208.3K — 1.00M 2.97M 321.7K 118.2K 4.62M 85.96% ↗
60 2019 ADAM H SCHECHTER Chief Executive Officer 208.3K — 1.00M 2.97M 321.7K 118.2K 4.62M 85.96% ↗
61 2019 JOHN D. RATLIFF Former Executive Vice President, Chief Executive Officer of Covance Drug Development 582.6K — 3.20M 750.0K — 37.3K 4.57M 86.43% ↗
62 2019 BRIAN J. CAVENEY Executive Vice President President, Diagnostics Chief Medical Officer 462.6K — 2.54M 120.4K 314.3K 9.8K 3.45M 77.20% ↗
63 2019 BRIAN J. CAVENEY Executive Vice President, Diagnostics Chief Medical Officer 462.6K — 2.54M 120.4K 314.3K 9.8K 3.45M 77.20% ↗
64 2019 LANCE V. BERBERIAN Executive Vice President Chief Information and Technology Officer 507.5K — 1.68M 151.4K 359.3K 9.8K 2.70M 67.57% ↗
65 2019 MARK S. SCHROEDER Executive Vice President, Diagnostics, Laboratory Operations and Global Supply Chain 406.3K 250.0K 1.51M 120.4K 245.5K 64.9K 2.59M 62.74% ↗
66 2019 MARK S. SCHROEDER Executive Vice President, President Diagnostics, Laboratory Operations and Global Supply Chain 406.3K 250.0K 1.51M 120.4K 245.5K 64.9K 2.59M 62.74% ↗
67 2019 MARK S. SCHROEDER Executive Vice President, President Diagnostics Laboratory Operations and Global Supply Chain 406.3K 250.0K 1.51M 120.4K 245.5K 64.9K 2.59M 62.74% ↗
68 2018 DAVID P. KING Chief Executive Officer 1.18M — 7.50M 1.82M 1.58M 189.1K 12.26M 75.96% ↗
69 2018 DAVID P. KING Former Chief Executive Officer 1.18M — 7.50M 1.82M 1.58M 189.1K 12.26M 75.96% ↗
70 2018 JOHN D. RATLIFF Executive Vice President, Chief Executive Officer of Covance Drug Development 679.8K — 5.10M 758.7K 762.6K 185.0K 7.49M 78.27% ↗
71 2018 JOHN D. RATLIFF Former Executive Vice President, Chief Executive Officer of Covance Drug Development 679.8K — 5.10M 758.7K 762.6K 185.0K 7.49M 78.27% ↗
72 2018 GARY M. HUFF Executive Vice President, Chief Executive Officer of LabCorp Diagnostics 600.0K — 1.25M 301.7K 489.3K 2.78M 5.43M 28.60% ↗
73 2018 GLENN A. EISENBERG Executive Vice President Chief Financial Officer 686.7K — 1.67M 403.7K 621.2K 53.0K 3.43M 60.33% ↗
74 2018 F. SAMUEL EBERTS III Senior Vice President Chief Legal Officer 530.0K — 499.7K 119.8K 331.1K 14.4K 1.49M 41.44% ↗
75 2017 DAVID P. KING Former Chief Executive Officer 1.15M — 6.75M 1.58M 1.96M 204.9K 11.65M 71.53% ↗
76 2017 DAVID P. KING Chief Executive Officer 1.15M — 6.75M 1.58M 1.96M 204.9K 11.65M 71.53% ↗
77 2017 JOHN D. RATLIFF Executive Vice President, Chief Executive Officer of Covance Drug Development 659.8K — 2.98M 697.6K 648.4K 13.0K 5.00M 73.56% ↗
78 2017 JOHN D. RATLIFF Former Executive Vice President, Chief Executive Officer of Covance Drug Development 659.8K — 2.98M 697.6K 648.4K 13.0K 5.00M 73.56% ↗
79 2017 GARY M. HUFF Executive Vice President, Chief Executive Officer of LabCorp Diagnostics 525.1K — 2.96M — 708.3K 66.6K 4.26M 69.52% ↗
80 2017 GLENN A. EISENBERG Executive Vice President Chief Financial Officer 666.5K — 1.59M 373.3K 746.2K 33.0K 3.41M 57.58% ↗
81 2017 F. SAMUEL EBERTS III Senior Vice President Chief Legal Officer 502.1K — 475.8K 111.4K 389.2K 49.6K 1.53M 38.42% ↗
82 2016 DAVID P. KING Chief Executive Officer 1.13M — 7.68M — 1.79M 251.6K 10.85M 70.79% ↗
83 2016 GLENN A. EISENBERG Executive Vice President Chief Financial Officer 653.4K — 2.80M — 679.6K 10.0K 4.14M 67.58% ↗
84 2016 DEBORAH L. KELLER Former Executive Vice President, Chief Executive Officer of Covance Drug Development 474.0K — 1.40M — 637.2K 1.33M 3.84M 36.41% ↗
85 2016 LANCE V. BERBERIAN Senior Vice President Chief Information Officer 396.1K — 1.40M — 206.0K 9.9K 2.01M 69.53% ↗
86 2016 LISA J. UTHGENANNT Senior Vice President Chief Human Resources Officer 440.2K — 614.1K — 318.9K 11.8K 1.38M 44.34% ↗
87 2016 F. SAMUEL EBERTS III Senior Vice President Chief Legal Officer 486.9K — 529.6K — 303.8K 39.4K 1.36M 38.95% ↗
88 2015 JAMES T. BOYLE, JR. Executive Vice President Chief Executive Officer, LabCorp Diagnostics 645.3K — 3.83M — 925.7K 25.2K 5.43M 70.60% ↗
89 2015 JOSEPH E. HERRING Former Executive Vice President Chief Executive Officer, Covance Drug Development 583.3K — 2.46M — 743.3K — 3.78M 64.94% ↗
90 2015 GLENN A. EISENBERG Executive Vice President Chief Financial Officer 635.4K — 2.11M — 676.9K 22.6K 3.45M 61.26% ↗
91 2015 DAVID P. KING Chief Executive Officer 1.04M — 7.88M — 1.67M 31.4K 3.41M 231.18% ↗
92 2015 F. SAMUEL EBERTS III Senior Vice President Chief Legal Officer 444.8K — 600.3K — 236.9K 14.6K 1.30M 46.30% ↗
93 2015 LANCE V. BERBERIAN Senior Vice President Chief Information Officer 373.6K — 520.0K — 199.0K 20.3K 1.11M 46.72% ↗
94 2014 David P. King Chief Executive Officer 1.01M — 7.54M — — — 10.47M 71.98% ↗
95 2014 DAVID P. KING Chief Executive Officer 1.01M — 7.54M — 1.60M 321.0K 10.47M 71.98% ↗
96 2014 JAMES T. BOYLE, JR. Executive Vice President Chief Executive Officer, LabCorp Diagnostics 632.6K — 3.67M — 835.6K 160.0K 5.29M 69.25% ↗
97 2014 James T. Boyle, Jr. Executive Vice President Chief Operating Officer 632.6K — 3.67M — — — 5.29M 69.25% ↗
98 2014 GLENN A. EISENBERG Executive Vice President Chief Financial Officer 338.5K — 3.95M — 344.6K 9.1K 4.64M 85.08% ↗
99 2014 William B. Hayes Former Executive Vice President Chief Financial Officer 277.2K — 855.6K — — — 1.61M 53.07% ↗
100 2014 F. SAMUEL EBERTS III Senior Vice President Chief Legal Officer 436.1K — 572.8K — 230.4K 91.8K 1.33M 43.03% ↗
101 2014 F. Samuel Eberts III Senior Vice President Chief Legal Officer 436.1K — 572.8K — — — 1.33M 43.03% ↗
102 2014 Mark E. Brecher Chief Medical Officer 352.2K — 507.8K — — — 1.07M 47.64% ↗
103 2013 David P. King Chief Executive Officer 1.01M — 7.45M — — — 9.28M 80.28% ↗
104 2013 DAVID P. KING Chief Executive Officer 1.01M — 7.45M — 790.6K 26.7K 9.28M 80.28% ↗
105 2013 James T. Boyle, Jr. Executive Vice President Chief Operating Officer 587.2K — 3.55M — — — 4.57M 77.80% ↗
106 2013 JAMES T. BOYLE, JR. Executive Vice President Chief Executive Officer, LabCorp Diagnostics 587.2K — 3.55M — 404.9K 22.2K 4.57M 77.80% ↗
107 2013 James T. Boyle Executive Vice President Chief Operating Officer 587.2K — 3.55M — 404.9K 22.2K 4.57M 77.80% ↗
108 2013 William B. Hayes Former Executive Vice President Chief Financial Officer 477.8K — 2.54M — — — 3.29M 77.13% ↗
109 2013 William B. Hayes Executive Vice President Chief Financial Officer 477.8K — 2.54M — 249.4K 25.1K 3.29M 77.13% ↗
110 2013 F. Samuel Eberts III Senior Vice President Chief Legal Officer 371.5K — 491.9K — — — 986.5K 49.87% ↗
111 2013 F. Samuel Eberts III Senior Vice President 371.5K — 491.9K — 109.8K 13.3K 986.5K 49.87% ↗
112 2013 F. SAMUEL EBERTS III Senior Vice President Chief Legal Officer 371.5K — 491.9K — 109.8K 13.3K 986.5K 49.87% ↗
113 2013 Mark E. Brecher Chief Medical Officer 345.3K — 491.9K — 107.4K 20.0K 964.6K 51.00% ↗
114 2013 Mark E. Brecher Chief Medical Officer 345.3K — 491.9K — — — 964.3K 51.01% ↗
115 2012 David P. King Chief Executive Officer 1.01M — 5.29M 2.25M 1.06M 24.4K 9.69M 77.79% ↗
116 2012 David P. King Chief Executive Officer 1.01M — 5.29M 2.25M 1.06M 24.4K 9.69M 77.79% ↗
117 2012 James T. Boyle, Jr. Executive Vice President Chief Operating Officer 511.9K — 1.70M 869.9K — — 3.56M 72.09% ↗
118 2012 James T. Boyle Executive Vice President Chief Operating Officer 511.9K — 1.70M 869.9K 430.6K 23.4K 3.56M 72.09% ↗
119 2012 James T. Boyle Executive Vice President Chief Operating Officer 511.9K — 1.70M 869.9K 430.6K 23.4K 3.56M 72.09% ↗
120 2012 William B. Hayes Executive Vice President Chief Financial Officer 470.0K — 1.69M 863.9K 292.7K 24.4K 3.37M 75.58% ↗
121 2012 William B. Hayes Executive Vice President Chief Financial Officer 470.0K — 1.69M 863.9K 292.7K 24.4K 3.37M 75.58% ↗
122 2012 William B. Hayes Former Executive Vice President Chief Financial Officer 470.0K — 1.69M 863.9K — — 3.37M 75.58% ↗
123 2012 Lidia L. Fonseca Senior Vice President Chief Information Officer 349.3K — 331.7K 171.3K 141.0K 10.0K 1.00M 50.05% ↗
124 2012 F. Samuel Eberts III Senior Vice President Chief Legal Officer 346.9K — 331.7K 171.3K — — 993.1K 50.64% ↗
125 2012 F. Samuel Eberts III Senior Vice President Chief Legal Officer 346.9K — 331.7K 171.3K 116.7K 12.4K 993.1K 50.64% ↗
126 2012 F. Samuel Eberts III Senior Vice President 346.9K — 331.7K 171.3K 116.7K 12.4K 993.1K 50.64% ↗
127 2011 David P. King Chief Executive Officer 993.8K — 4.55M — 2.02M 25.7K 11.06M 41.11% ↗
128 2011 David P. King Chief Executive Officer 993.8K — 4.55M 3.29M 2.02M 25.7K 11.06M 70.81% ↗
129 2011 James T. Boyle Executive Vice President Chief Operating Officer 501.9K — 1.46M 1.06M 803.4K 27.5K 3.94M 63.85% ↗
130 2011 James T. Boyle Chief Operating Officer 501.9K — 1.46M 1.06M 803.4K 27.5K 3.94M 63.85% ↗
131 2011 James T. Boyle Executive Vice President Chief Operating Officer 501.9K — 1.46M 1.06M 803.4K 27.5K 3.94M 63.85% ↗
132 2011 William B. Hayes Executive Vice President Chief Financial Officer 465.2K — 1.44M 1.04M 629.3K 26.4K 3.76M 66.15% ↗
133 2011 William B. Hayes Executive Vice President Chief Financial Officer 465.2K — 1.44M 1.04M 629.3K 26.4K 3.76M 66.15% ↗
134 2011 William B. Hayes Executive Vice President and Chief Financial Officer 465.2K — 1.44M 1.04M 629.3K 26.4K 3.76M 66.15% ↗
135 2011 Andrew S. Walton Executive Vice President 368.8K — 780.4K 563.0K 437.0K 19.4K 2.21M 60.82% ↗
136 2011 Lidia L. Fonseca Senior Vice President Chief Information Officer 344.7K — 299.4K 214.8K 278.7K 21.4K 1.17M 43.79% ↗
137 2011 Lidia L. Fonseca Senior Vice President, Chief Information Officer 344.7K — 299.4K 214.8K 278.7K 21.4K 1.17M 43.79% ↗
138 2010 David P. King Chief Executive Officer 885.3K — 4.04M 2.65M 1.90M 59.3K 9.67M 69.20% ↗
139 2010 David P. King Chief Executive Officer 885.3K — 4.04M 2.65M 1.90M 59.3K 9.67M 69.20% ↗
140 2010 James T. Boyle Executive Vice President Chief Operating Officer 450.0K — 1.73M 852.4K 702.8K 64.5K 3.86M 66.76% ↗
141 2010 James T. Boyle Chief Operating Officer 450.0K — 1.73M 852.4K 702.8K 64.5K 3.86M 66.76% ↗
142 2010 William B. Hayes Executive Vice President Chief Financial Officer 436.8K — 1.37M 901.0K 589.5K 52.3K 3.44M 65.89% ↗
143 2010 William B. Hayes Executive Vice President and Chief Financial Officer 436.8K — 1.37M 901.0K 589.5K 52.3K 3.44M 65.89% ↗
144 2010 William B. Hayes Executive Vice President and Chief Financial Officer 436.8K — 1.37M 901.0K 589.5K 52.3K 3.44M 65.89% ↗
145 2010 Andrew J. Conrad 423.7K — 820.8K 541.7K 538.0K 26.2K 2.35M 57.97% ↗
146 2010 Andrew S. Walton Executive Vice President 347.2K — 750.6K 491.7K 412.7K 50.8K 2.08M 59.79% ↗
147 2010 Andrew S. Walton Executive Vice President 347.2K — 750.6K 491.7K 412.7K 50.8K 2.08M 59.79% ↗
148 2009 David P. King Chief Executive Officer 810.0K — 4.03M 2.43M 1.42M 46.9K 8.94M 72.27% ↗
149 2009 David P. King Chief Executive Officer 810.0K — 4.03M 2.43M 1.42M 46.9K 8.94M 72.27% ↗
150 2009 Don M. Hardison Chief Operating Officer 466.9K — 1.69M 1.02M 556.6K 1.15M 4.96M 54.66% ↗
151 2009 William B. Hayes Executive Vice President and Chief Financial Officer 419.3K — 1.48M 887.5K 577.5K 46.1K 3.50M 67.53% ↗
152 2009 William B. Hayes Executive Vice President and Chief Financial Officer 419.3K — 1.48M 887.5K 577.5K 46.1K 3.50M 67.53% ↗
153 2009 Andrew S. Walton Executive Vice President 335.0K 24.8K 768.5K 461.8K 290.1K 43.5K 1.95M 63.08% ↗
154 2009 Andrew S. Walton Executive Vice President 335.0K 24.8K 768.5K 461.8K 290.1K 43.5K 1.95M 63.08% ↗
155 2009 F. Samuel Eberts Senior Vice President Chief Legal Officer 311.6K — 294.2K 201.3K 177.6K 27.9K 1.05M 47.06% ↗
156 2008 David P. King Chief Executive Officer 791.7K 160.0K 4.15M 2.44M 605.7K 45.8K 8.30M 79.39% ↗
157 2008 Bradford T. Smith Executive Vice President and Chief Legal Officer 558.3K 98.0K 2.48M 1.76M 260.3K 46.8K 6.98M 60.74% ↗
158 2008 Don M. Hardison Chief Operating Officer 478.8K 100.0K 1.85M 1.09M 188.5K 34.6K 3.81M 77.21% ↗
159 2008 William B. Haas Executive Vice President Esoteric Business 146.5K — 1.82M 845.0K 111.6K 496.4K 3.47M 76.78% ↗
160 2008 William B. Hayes Executive Vice President and Chief Financial Officer 413.3K 55.0K 1.53M 900.5K 87.3K 45.8K 3.07M 79.20% ↗
161 2008 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer and Medical Director 401.3K 51.0K 1.41M 891.3K 125.1K 42.3K 3.02M 76.38% ↗
162 2008 Don M. Hardison Chief Operating Officer 478.8K 100.0K 749.4K 397.2K 188.5K 34.6K 2.01M 56.91% ↗
163 2007 David P. King Chief Executive Officer 750.0K — 2.01M 2.16M 1.46M 50.5K 6.52M 63.84% ↗
164 2007 Bradford T. Smith Executive Vice President and Chief Legal Officer 540.0K — 2.32M 1.04M 825.5K 46.0K 5.06M 66.31% ↗
165 2007 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer and Medical Director 385.6K — 1.56M 577.1K 328.2K 36.8K 3.02M 70.81% ↗
166 2007 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer and Medical Director 385.6K — 1.56M 577.1K 328.2K 36.8K 3.02M 70.81% ↗
167 2007 William B. Hayes Executive Vice President and Chief Financial Officer 391.7K — 1.10M 791.1K 437.3K 46.9K 2.81M 67.49% ↗
168 2007 William B. Haas Executive Vice President Esoteric Business 341.2K — 1.03M 436.5K 297.1K 46.7K 2.24M 65.68% ↗
169 2007 William B. Haas Executive Vice President Esoteric Business 341.2K — 1.03M 436.5K 297.1K 46.7K 2.24M 65.68% ↗
170 2006 Thomas P. Mac Mahon Chairman and Chief Executive Officer 989.5K — 12.44M 5.76M 2.04M 67.6K 21.51M 84.64% ↗
171 2006 Richard L. Novak Executive Vice President, Strategic Planning 525.0K — 4.13M 2.12M 850.6K 53.7K 7.76M 80.39% ↗
172 2006 Bradford T. Smith Executive Vice President and Chief Legal Officer 453.9K — 1.34M 1.02M 595.9K 33.7K 3.70M 63.64% ↗
173 2006 Bradford T. Smith Executive Vice President and Chief Legal Officer 453.9K — 1.34M 1.02M 595.9K 47.6K 3.52M 66.89% ↗
174 2006 David P. King Chief Executive Officer 450.0K — 885.4K 567.2K 642.1K 44.7K 2.63M 55.31% ↗
175 2006 David P. King Executive Vice President and Chief Operating Officer 450.0K — 885.4K 567.2K 642.1K 44.7K 2.63M 55.31% ↗
176 2006 William B. Hayes Executive Vice President and Chief Financial Officer 350.0K — 813.8K 337.6K 431.1K 49.2K 2.00M 57.44% ↗
177 2006 William B. Hayes Executive Vice President and Chief Financial Officer 350.0K — 813.8K 337.6K 431.1K 49.2K 2.00M 57.44% ↗
178 2005 Thomas P. Mac Mahon President and Chief Executive Officer 929.7K 1.32M 1.93M 175.0K — — 4.18M 50.34% ↗
179 2005 Richard L. Novak Executive Vice President of Strategic Planning and Corporate Development 505.7K 542.3K 633.3K 65.0K — — 1.68M 41.53% ↗
180 2005 Bradford T. Smith Executive Vice President, Chief Legal Officer, and Secretary 437.5K 444.1K 514.8K 45.0K — — 1.40M 40.09% ↗
181 2005 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer, and Medical Director 357.7K 302.7K 402.3K 30.0K — — 1.06M 40.68% ↗
182 2005 David P. King Executive Vice President and Chief Operating Officer 341.0K 216.7K 402.3K 30.0K — — 960.0K 45.03% ↗
183 2004 Thomas P. Mac Mahon President and Chief Executive Officer 885.4K 1.59M — 288.4K — — 2.47M 11.67% ↗
184 2004 Richard L. Novak Executive Vice President and Chief Operating Officer 483.1K 603.0K — 135.4K — — 1.09M 12.47% ↗
185 2004 Richard L. Novak Executive Vice President of Strategic Planning and Corporate Development 483.1K 603.0K — 135.4K — — 1.09M 12.47% ↗
186 2004 Bradford T. Smith Executive Vice President, Chief Legal Officer, and Secretary 417.0K 518.8K — 105.0K — — 935.7K 11.22% ↗
187 2004 Wesley R. Elingburg Executive Vice President, Chief Financial Officer, and Treasurer 417.0K 500.0K — 105.0K — — 917.0K 11.45% ↗
188 2004 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer, and Medical Director 341.4K 311.4K — 50.4K — — 652.8K 7.72% ↗
189 2004 David P. King Executive Vice President and Chief Operating Officer 310.0K 174.2K — 45.0K — — 484.2K 9.29% ↗
190 2003 Thomas P. Mac Mahon President and Chief Executive Officer 845.6K 1.30M — 288.4K — — 2.14M 13.45% ↗
191 2003 Richard L. Novak Executive Vice President of Strategic Planning and Corporate Development 469.0K 571.7K — 135.4K — — 1.04M 13.01% ↗
192 2003 Richard L. Novak Executive Vice President and Chief Operating Officer 469.0K 571.7K — 135.4K — — 1.04M 13.01% ↗
193 2003 Bradford T. Smith Executive Vice President, Chief Legal Officer, and Secretary 399.8K 458.3K — 105.0K — — 858.1K 12.24% ↗
194 2003 Wesley R. Elingburg Executive Vice President, Chief Financial Officer, and Treasurer 399.8K 424.2K — 105.0K — — 824.0K 12.74% ↗
195 2003 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer, and Medical Director 326.7K 262.6K — 50.4K — — 589.3K 8.55% ↗
196 2003 David P. King Executive Vice President and Chief Operating Officer — — — — — — — — ↗
197 2002 Thomas P. Mac Mahon President and Chief Executive Officer 825.0K 1.46M 14.16M 491.4K — — 16.45M 89.07% ↗
198 2002 Thomas P. Mac Mahon President and Chief Executive Officer 825.0K 1.46M 14.16M 491.4K — — 16.45M 89.07% ↗
199 2002 Richard L. Novak Executive Vice President and Chief Operating Officer 454.7K 647.9K 6.65M 230.8K — — 7.76M 88.76% ↗
200 2002 Richard L. Novak Executive Vice President and Chief Operating Officer 454.7K 647.9K 6.65M 230.8K — — 7.76M 88.76% ↗
201 2002 Bradford T. Smith Executive Vice President, Chief Legal Officer, and Secretary 387.5K 503.6K 5.16M 178.8K — — 6.05M 88.22% ↗
202 2002 Bradford T. Smith Executive Vice President, Chief Legal Officer, and Secretary 387.5K 503.6K 5.16M 178.8K — — 6.05M 88.22% ↗
203 2002 Wesley R. Elingburg Executive Vice President, Chief Financial Officer, and Treasurer 387.5K 480.8K 5.16M 178.8K — — 6.02M 88.55% ↗
204 2002 Wesley R. Elingburg Executive Vice President, Chief Financial Officer, and Treasurer 387.5K 480.8K 5.16M 178.8K — — 6.02M 88.55% ↗
205 2002 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer, and Medical Director 299.7K 271.9K 2.47M 85.8K — — 3.04M 84.02% ↗
206 2002 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer, and Medical Director 299.7K 271.9K 2.47M 85.8K — — 3.04M 84.02% ↗
207 2001 Thomas P. Mac Mahon President and Chief Executive Officer 812.5K 1.85M 4.91M 445.6K — — 7.57M 70.71% ↗
208 2001 Thomas P. Mac Mahon President and Chief Executive Officer 812.5K 1.85M 4.91M 445.6K — — 7.57M 70.71% ↗
209 2001 Richard L. Novak Executive Vice President and Chief Operating Officer 433.3K 691.7K 1.98M 194.4K — — 3.11M 70.06% ↗
210 2001 Richard L. Novak Executive Vice President and Chief Operating Officer 433.3K 691.7K 1.98M 194.4K — — 3.11M 70.06% ↗
211 2001 Wesley R. Elingburg Executive Vice President, Chief Financial Officer, and Treasurer 365.8K 573.6K 1.59M 140.0K — — 2.53M 68.36% ↗
212 2001 Wesley R. Elingburg Executive Vice President, Chief Financial Officer, and Treasurer 365.8K 573.6K 1.59M 140.0K — — 2.53M 68.36% ↗
213 2001 Bradford T. Smith Executive Vice President, Chief Legal Officer, and Secretary 365.8K 532.6K 1.59M 140.0K — — 2.49M 69.49% ↗
214 2001 Bradford T. Smith Executive Vice President, Chief Legal Officer, and Secretary 365.8K 532.6K 1.59M 140.0K — — 2.49M 69.49% ↗
215 2001 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer, and Medical Director 285.0K 298.7K 595.1K 54.4K — — 1.18M 55.10% ↗
216 2001 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer, and Medical Director 285.0K 298.7K 595.1K 54.4K — — 1.18M 55.10% ↗
217 2000 Thomas P. Mac Mahon President and Chief Executive Officer 741.7K 726.3K 3.46M 362.4K — — 4.93M 77.58% ↗
218 2000 Richard L. Novak Executive Vice President and Chief Operating Officer 391.7K 427.2K 1.70M 138.4K — — 2.51M 72.93% ↗
219 2000 Wesley R. Elingburg Executive Vice President, Chief Financial Officer, and Treasurer 313.3K 254.4K 758.3K 79.2K — — 1.33M 63.16% ↗
220 2000 Bradford T. Smith Executive Vice President, Chief Legal Officer, and Secretary 313.3K 245.4K 758.3K 79.2K — — 1.32M 63.59% ↗
221 2000 Myla P. Lai-Goldman Executive Vice President, Chief Scientific Officer, and Medical Director 256.7K 209.4K 388.6K 56.4K — — 854.7K 52.07% ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2026-04-10 DEFA14A ↗
2026-04-10 DEF 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-04 10-Q ↗
2026-04-30 8-K ↗
2026-04-28 SC 13G ↗
2026-04-10 DEFA14A ↗
2026-04-10 DEF 14A ↗
2026-04-10 ARS ↗
2026-04-09 8-K ↗
2026-03-31 8-K ↗
2026-03-30 4 ↗
2026-03-30 4 ↗

Executive team

NameTitleCompensationGender
Adam H. Schechter President, Chief Executive Officer & Chairman 4M male
Julia Wang Chief Financial Officer & Executive Vice President 2M female
Anita Z. Graham Executive Vice President & Chief Human Resources Officer 2M female
Brian J. Caveney EVice President, President of Early Development Research Laboratories and Chief Medical & Scientific Officer 1M —
Mark S. Schroeder Executive Vice President, President of Diagnostics Laboratories & Chief Operating Officer 1M male
Megan D. Bailey Executive VP and President of Central Laboratory Services & International Labcorp 1M female
Akinbolade Oyegunwa Executive Vice President and Chief Information & Technology Officer 876.6K male
Peter J. Wilkinson Senior Vice President & Chief Accounting Officer — male
Amy Summy EVP, Chief Marketing Officer & Consumer Health Lead — female
Bryan T. Vaughn Executive Vice President of Diagnostics — male
Christin O'Donnell Vice President of Investor Relations — —
Jonathan C. Meltzer Executive Vice President of Operations — male
ESG Rating
C+
MEDICAL - DIAGNOSTICS & RESEARCH
2016
E (Environmental)
45.0 / 61.3
Company / Sector avg.
S (Social)
50.4 / 65.4
Company / Sector avg.
G (Governance)
58.7 / 64.9
Company / Sector avg.
ESG Total
51.4 / 63.8
Company / Sector avg.
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
Transaction Date Disclosed Senator State Owner Type Amount Link
2023-08-22 2023-09-18 Dan Sullivan AK Joint Sale (Full) $1,001 - $15,000 ↗
2019-04-26 2019-05-03 James Inhofe OK Self Sale (Full) $50,001 - $100,000 ↗
2018-05-03 2018-05-14 James Inhofe OK Self Sale (Partial) $15,001 - $50,000 ↗
House Trading Activity
Transaction Date Disclosed Representative District Owner Type Amount Link
2026-02-19 2026-03-12 Tony Wied WI08 Joint Purchase $15,001 - $50,000 ↗
2026-02-11 2026-03-11 April Delaney MD06 — Purchase $1,001 - $15,000 ↗
2026-02-04 2026-03-11 April Delaney MD06 — Purchase $1,001 - $15,000 ↗
2026-01-28 2026-02-03 April Delaney MD06 — Purchase $1,001 - $15,000 ↗
2025-11-17 2025-12-09 April Delaney MD06 — Purchase $1,001 - $15,000 ↗
2025-10-31 2025-11-05 April Delaney MD06 — Purchase $1,001 - $15,000 ↗
2025-10-29 2025-11-05 April Delaney MD06 — Purchase $1,001 - $15,000 ↗
2025-10-27 2025-11-14 Ro Khanna CA17 Spouse Sale $1,001 - $15,000 ↗
2025-06-27 2025-07-10 Ro Khanna CA17 — Sale $1,001 - $15,000 ↗
2025-05-15 2025-06-02 Rob Bresnahan PA08 — Purchase $1,001 - $15,000 ↗
2025-04-08 2025-05-08 Rob Bresnahan PA08 — Sale (Full) $1,001 - $15,000 ↗
2025-03-31 2025-04-07 Gilbert Cisneros CA31 — Sale (Partial) $1,001 - $15,000 ↗
2025-02-28 2025-03-21 John Delaney MD06 — Purchase $1,001 - $15,000 ↗
2025-02-27 2025-03-21 John Delaney MD06 — Purchase $1,001 - $15,000 ↗
2025-02-25 2025-03-28 Rob Bresnahan PA08 — Purchase $1,001 - $15,000 ↗
2025-02-17 2025-03-21 John Delaney MD06 — Purchase $1,001 - $15,000 ↗
2025-02-08 2025-03-21 John Delaney MD06 — Purchase $1,001 - $15,000 ↗
2025-02-05 2025-03-21 John Delaney MD06 — Purchase $1,001 - $15,000 ↗
2024-06-14 2024-07-08 Ro Khanna CA17 — Purchase $1,001 - $15,000 ↗
2024-03-20 2024-04-05 Ro Khanna CA17 Spouse Sale $1,001 - $15,000 ↗
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research